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INTRODUCTION AND AIMS OF THE THESIS 
Albumin is the most abundant protein in human blood plasma. After being produced 
in the liver, it circulates as a polypeptide chain of 585 amino acids which is cross-
linked by 17 disulphide bonds. Albumin has a molecular mass of 66,439 Dalton, a 
molecular radius of approximately 36 Å, and a pI of 5.6.1,2 Although physical and 
chemical data support a heart shaped structure for albumin,3 the molecule can rapidly 
change conformation.1 Constituting 60% of the total plasma protein, albumin 
contributes to about 80% of the colloid osmotic pressure, and binds a variety of 
ligands such as fatty acids, bilirubin, calcium, hormones, and certain drugs.  
Albumin is excreted in the urine in very small amounts of less than 30 mg per day in 
healthy individuals. It is assumed that albumin passes through the glomerular filtration 
barrier, and is reabsorbed by the proximal tubular cells by receptors such as megalin 
and cubulin, after which it is delivered to the lysosomal system and broken down to 
amino acids which are delivered back into the circulation.4,5 Increased amounts of 
albumin can appear in the urine, resulting from increased glomerular filtration and/or 
altered tubular reabsorption.  
 
ALBUMINURIA AS AN ESTABLISHED RISK MARKER 
The excretion of small amounts of albumin in the urine (microalbuminuria, 30-300 
mg/24 hour) has been established as one of the earliest indicators of nephropathy in 
patients with diabetes mellitus.6-10 Furthermore, it has been recognized as a powerful 
marker and predictor for cardiovascular disease in diabetes as well as in the general 
population.11-13 The underlying mechanism of leakage of albumin into the urine is 
suggested to be endothelial dysfunction which is presumably not only confined to the 
kidneys, but might be an indication of generalized endothelial dysfunction.14   
 
THE MEASUREMENT OF ALBUMINURIA 
Given the fact that cardiovascular disease is the leading cause of death in 
industrialized countries, it is of great importance to identify those at risk for 
cardiovascular disease in order to be able to start preventive treatment. In this respect 
assessment of urinary albumin may be a strategy.   
The first laboratory tests developed to detect urinary albumin (dipstick tests) could 
only measure concentrations of 300 mg/24 hour and above. The first analytical test 
that could measure lower albumin concentrations was a radio-immuno assay (RIA), 
using 125I labeled albumin which is based on the binding of albumin and the labeled 
albumin to form an immune complex. The RIA method is consuming and expensive, 
and therefore an immunonephelometry based automatic assay was developed in 
which albumin forms an immunochemical reaction. Antibody and antigen are mixed, 
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resulting in small aggregates. These aggregates will scatter light and the amount of 
scatter can consequently be measured. In the clinical setting, assessment of 
microalbuminuria (30-300 mg/day by immunonephelometry) has been established as 
a valuable risk marker for the early detection of nephropathy in both type I and type II 
diabetes mellitus. Nephelometry is a commonly used method in hospital diagnostics 
and clinical research.  
 
ALBUMINURIA AND STORAGE OF SPECIMENS (PART I OF THIS THESIS)              
In the past decade, several large epidemiological studies have investigated predictors 
for renal and cardiovascular disease. Frozen blood samples and/or urine specimens 
are often used to assess the analyte of interest in these studies. This has the advantage 
that samples can be processed in a relatively short time-span in which laboratory 
conditions can be carefully controlled and analytical drift in the assay can be 
prevented. It is questionable whether storage of samples at -20°C, but also at -80°C, is 
permissible for the correct assessment of albumin in the urine. In part I of the thesis 
this issue was addressed. In chapter 2 the effect of prolonged frozen storage at -20°C 
and different mixing methods of the samples on the measured albumin concentration 
was investigated. The effect of prolonged frozen storage at -20°C on the predictive 
power of albuminuria for mortality was studied in chapter 3, and chapter 4 describes 
the role of urinary pH on a decline in albumin concentration when assessed by 
immunonephelometry. In chapter 5 we investigated whether a potential decrease in 
albumin concentrations could be prevented by storage of urine samples at -80°C. In 
this chapter, the effect of frozen storage on different methods to assess albumin, such 
as immunonephelometry and a recently developed High Performance Liquid 
Chromatography (HPLC) method, was also studied.  
 
ALBUMINURIA AND METHODS OF ANALYSIS (PART II OF THIS THESIS) 
In chapter 6 we describe several aspects which should be taken into consideration 
when making the choice between the different ways to measure albumin in urine: as 
urinary albumin concentration, albumin:creatinine ratio or as 24 hour urine collection. 
This chapter also contains a thorough discussion on what the gold standard for 
assessing albuminuria should be: 24 hour urine collections or spot morning urine 
samples.            
 
As previously described, albumin in the urine is traditionally measured by 
immunochemical based methods using anti-albumin antibodies, such as 
immunonephelometry. Several studies, however, have shown that urine contains 
























Figure 1. Schematic overview of the HPLC method developed to measure total albumin. 
 
 
conventional albumin antibodies.15-18 This other form of albumin is hypothesized to be 
a product of decreased lysosomal activity in vivo, resulting in modifications or changes 
in ligand binding and consequently in a disruption of the immuno-reactive binding site 
of the molecule. This so-called ‘immunochemically nonreactive albumin’ is in terms of 
shape, size and charge similar to native albumin and can be detected by a new 
developed HPLC method, based on size-exclusion (figure 1).19 This method is said to 
measure both immunochemically reactive and immunochemically nonreactive 
albumin (total albumin concentration).    
Chapter 7 compares the albumin concentration, measured by immunonephelometry 
and HPLC, with respect to the prevalence of microalbuminuria and the association 
with cardiovascular risk factors and peripheral vascular disease. Chapter 8 describes 
the predictive performance of albumin assessed by both methods for both 
cardiovascular and total mortality.  
 
All investigations in this thesis have been performed within the scope of the 
Prevention of REnal and Vascular ENdstage Disease (PREVEND) Study in Groningen, 
the Netherlands. The PREVEND study started in 1997, and is a prospective, cohort 
study with sequential follow-up to investigate the natural course of albuminuria and its 
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Albuminuria is a predictor of cardiovascular and renal disease in patients with diabetes 
and the general population. Urinary albumin is usually assessed in fresh samples, 
whereas large cohort and intervention studies often use frozen samples after relatively 
long periods of freezing. The aim of our study was to investigate whether prolonged 
freezing affects urinary albumin concentrations (UAC), and whether the way of 
sample-handling after thawing is relevant.  
Frozen urine samples (n=1785) were selected from the PREVEND study. In this cohort 
study, fresh urine samples have been used to assess albumin concentrations by 
immunonephelometry. The fresh concentration was used to select samples in 6 
different UAC categories up to 500 mg/L, after storage (-20°C) in 5 categories 
between 3 and 24 months. After thawing, samples were randomly assigned to three 
ways of sample-handling: no sample-handling, hand-inversions and vortex-mixing.     
Without sample-handling, there was a significant difference in UAC after 3-5 months of 
storage: -34.9 (28.6)% (mean (SD), (P<0.001). Beyond 8 months of storage the 
difference stabilized between -50% and -60%. With hand-inversions and vortex-mixing, 
no significant decreases were observed after 3-5 months of storage: -5.3 (30.6)% (NS), 
and -2.6 (27.5)% (NS), respectively. After 5-8 months there were differences of -12.7 
(24.3)%, (P<0.001) and -11.7 (26.2)%, P<0.001, respectively. The differences stabilized 
at approximately -30% beyond 8 months of storage for both hand-inversions and 
vortex-mixing. 
Prolonged frozen storage of urine samples results in assessment of falsely low UACs 
after thawing. The great variability in percentage changes indicates large differences 
between individual samples in their response to freezing. It is therefore 
recommendable to use fresh urine samples. When freezing is applied, adequate 
sample-handling can prevent significant decreases in UACs where storage is shorter 
than 5 months.  
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INTRODUCTION 
Microalbuminuria, defined as a urinary albumin concentration  (UAC) between 20-200 
mg/L, is an early predictor of diabetic nephropathy.1-6 In addition, microalbuminuria is 
a marker of cardiovascular morbidity and mortality, both in patients with diabetes 
mellitus and in the general population.7-17 Consequently, there is great interest in 
screening for microalbuminuria in these groups. In cohort studies urine samples are 
often kept frozen at -20°C prior to analysis. Although some study results have 
indicated no effect of freezing on UAC,18-23 other studies have found erroneously low 
values when samples were frozen at -20°C.24-27 Only a few studies investigated the 
effect of longer storage periods, but these studies were small and samples were in the 
macroalbuminuric range (>200 mg/L). 
We investigated the effects of storage at -20°C for up to 24 months, mixing methods, 





Urine samples were collected during the prospective PREVEND study in the general 
population, initiated to investigate urinary albumin excretion as a predictor of renal 
and cardiovascular disease.28 The participants were asked to collect urine for two 24 
hour periods, and to store it in two 3 liter plastic containers at 7°C and deliver it within 
2 days to the out-patients clinic. Immediately after delivery, the urine sample volume 
was determined, and a portion of each of the 24 hour samples was stored in 2 ml 
polypropylene aliquots at -20°C for albumin assessment after freezing. For 
measurement of UAC in fresh samples, portions were kept at 7°C in 10 ml polystyrene 
tubes until UAC was measured. All participants gave written informed consent. The 
PREVEND study was approved by the local medical ethics committee and was 
conducted in accordance with the guidelines of the Declaration of Helsinki. On the 
basis of the fresh urinary albumin concentration and duration of storage, we selected 
1785 urine samples for the study. Samples were obtained from storage 1-3 days 
before analysis, thawed at 7°C, and randomly assigned to 3 groups. Samples in the first 
group (I; n=600) were not mixed before analysis, samples in the second group (II; 
n=596) were subjected to 3-4 hand inversions before analysis, and samples in the third 
group (III; n=689) were vortex-mixed for 5-10 seconds. All samples were centrifuged 
before  analysis, and analyzed directly after centrifuging. At the time of analysis the 
samples were at room temperature. Samples were both thawed and analyzed within 
the same laboratory. UAC was measured by immunonephelometry (Dade Behring 
Diagnostics) with a lower limit of detection of 2.3 mg/L (defined as the concentration 
CHAPTER 2 
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of the lowest calibration solution). The intra- and interassay CVs, evaluated in our 
laboratory, were 2.7 and 4.5%, respectively. 
 
STATISTICAL ANALYSES 
All data were analyzed with SPSS 12.0 software. Data are presented as mean (SD) 
percentage differences in albumin, which had a Gaussian distribution. Differences 
among groups were assessed by ANOVA, and differences between groups by post-
hoc analysis according to Tukey. t-Tests for single groups were used to test whether 
differences in UAC were statistically different from zero. To investigate whether the 
effect of duration of storage and baseline UAC were independent of UAC difference, 
we performed multiple linear regression analysis using percentage UAC difference as 
an independent variable. Potential interactions were tested. Statistical significance was 




After 3 to 5 months of storage, there was a considerably larger change in UAC in 
unmixed samples than in samples that were subjected to either vortex-mixing or hand- 
inversions [-34.9 (28.6)% versus -5.3 (30.6)% and -2.6 (27.5)%, respectively; P<0.001]. 
These latter two changes were not different from zero. Only the samples of groups II 
and III were included in further analyses. The difference amounted to -23.7 (26.2)% 
and -26.1 (24.7)% after 18-24 months of storage respectively (P<0.001 in both groups). 
Overall post-hoc analysis showed no differences in albumin decrease between groups 
II and III (P>0.05) for all durations of storage and concentration categories; therefore, 
for further analysis, we combined the 2 groups. The combined data for percentage 
change according to concentration categories and duration of storage are shown in 
table 1. The UAC difference stabilized at ~30% after 8 months of storage. The large 
SD in the changes in UAC suggests large differences amongst samples in the response 
of UAC to freezing.  
The percentage changes in albumin concentration in individual samples after 3-5 
months or 18-24 months are shown in figure 1. Specimens with a high baseline UAC 
responded differently to freezing than those with a low UAC. A maximum change of   
-28 (33)% was seen in the 10-20 mg/L category. The samples in concentration group 
200-500 mg/L showed a markedly smaller compared with the samples in the other 
groups (P<0.001). Multiple regression analysis showed no interaction between initial 
UAC and duration of storage.  
  




























































































































































































































































































































































































































































































































































































































































































































































Figure 1. Percentage differences in UAC in the mixed samples after 3-5 months (z) and 18-24 months of 
freezing (). Percentage differences between albumin concentrations measured on two consecutive days 




The data indicate that urine samples can be stored for 5 months without great changes 
in mean albumin concentration when samples are mixed adequately after thawing. 
The change in UAC varies among samples with large variations in the lower 
concentration ranges. Although several studies have investigated the effect of freezing 
on UAC, most studied only shorter storage times, different concentrations of albumin 
and smaller numbers of urine samples. Innanen et al. 21 and Collins et al.22 found no 
substantial difference after 6 months. Two authors reported no substantial change in 
UAC after 2429 and 26 months;30 the UACs in those studies samples, however, were 
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albumin was seen in 10 samples, a change consistent with the ~10% decrease we 
found in samples with a concentration of 200-500 mg/L. Shield et al.30 also reported 
that urine samples with higher albumin concentrations are less prone to change in 
UAC after freezing for up to 6 months. We emphasize the importance of the effect of 
freezing on samples in the microalbuminuric (20-200 mg/L) range because 
microalbuminuria has been established as an early predictor of cardiovascular and 
renal disease.7,14,16,17  
Why UAC declines during freezing is still unknown. It may be that albumin molecules 
are trapped in the precipitate because of an alteration in pH of the urine samples 
during freezing and thawing.20,31 Bacterial contaminations may also affect UAC. Falsely 
low values may reflect hydrolysis by bacterial proteases.32 Moreover, storage tube 
materials might play a role in preventing albumin loss after freezing. Collins et al.,22 
however, found no difference in concentration when they studied the effect of 
different tube materials on UAC after freezing. Conformational changes that occur 
during freezing may lead to loss of the antibody recognition site that is needed to 
measure albumin with immunochemical methods.22,32  
Our study is limited by the fact that we did not investigate possible mechanisms of loss 
of UAC or the effect of storage at -70°C or -80°C, at which temperature MacNeil et 
al.26 found no substantial decrease in UAC after 160 days of storage. We found a large 
variability in UAC change, also a common phenomenon in other studies.18,21,24,25,33,34 A 
thorough investigation of all the circumstances that might be involved in the change in 
albumin after freezing was beyond the scope of our study.  
We recommend that albumin should be measured in fresh urine samples whenever 
possible because specimens respond differently to freezing and thawing and because 
albumin appears to be less stable in normo- and microalbuminuric samples than in 
samples with higher albumin concentrations. This effect of freezing must be taken into 
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Large epidemiological and intervention studies often use frozen urine to assess 
albuminuria. It is, however, still unknown whether results are adversely affected by 
freezing. We compared the prospective prediction of mortality in the general 
population by albuminuria assessed from fresh urine and urine after prolonged frozen 
storage at -20°C. 
Urinary albumin concentration (UAC) was assessed by immunonephelometry in urine 
samples from 3485 subjects of the general population that were asked to collect two 
24 hour urine collections. UAC was assessed fresh and after storage at -20°C for 7 ± 
0.4 years. During follow-up from baseline (’97-’98) through December 2004, 340 
subjects died.  
ROC curve analyses showed that both albuminuria assessed from fresh urine (AUC 
0.80 ± 0.014, P<0.001) and frozen urine samples (AUC 0.74 ± 0.016, P<0.001) 
significantly predict mortality, but the predictive value of frozen samples was 
significantly lower (P=0.006). After frozen storage the mean change in albumin 
concentration was -31 ± 28%. Freezing resulted in an increase in measurement error 
in urinary albumin assessment. The overall additional measurement error (CVfreezing) 
resulting from frozen storage was 18% (CVanalytical+biological being 25% and CVtotal 31%).    
Our study is the first prospective report on a decrease in predictive properties of 
albuminuria for mortality after prolonged frozen storage of urine samples. Our study is 
also the first to report on the introduction of an additional measurement error by 
freezing, along with a decline in albumin concentrations. The introduction of an 
additional measurement error and the decline in predictive properties is of importance 
for the interpretation and design of epidemiological studies, screening programs, and 
intervention trials.  
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INTRODUCTION 
Microalbuminuria, defined as a urinary albumin excretion between 30 and 300 
mg/day, is in wide clinical use as an early predictor of diabetic nephropathy. More 
recently, interest has started to rise in microalbuminuria as a predictor of 
cardiovascular morbidity and mortality, both in patients with diabetes mellitus and in 
the general population.1 In large epidemiological studies and intervention trials, 
biological samples are often stored frozen before assessment of the analyte of interest. 
This has the advantage that samples can be handled within a relatively short time-span, 
in which laboratory conditions can be carefully controlled. It is questionable whether 
this is advantageous for the assessment of urinary albumin. Several studies have shown 
that prolonged frozen storage of urine samples at -20°C can result in detection of 
falsely low urinary albumin concentrations (UAC), especially if urine specimens with 
albumin concentrations in the microalbuminuric range are concerned.2-5 Besides this, 
many authors have suggested the introduction of an additional source of 
measurement error by frozen storage,4-10 but there are no studies that have 
substantiated this. It is furthermore not known whether prolonged frozen storage of 
urine samples prior to assessment affects performance of albuminuria as a predictor of 
events.  
We investigated prospectively whether prolonged frozen storage of urine samples 
prior to assessment results in an altered performance of albuminuria as a predictor of 
mortality. We furthermore investigated whether freezing results in the introduction of 





The PREVEND (Prevention of REnal and Vascular ENd-stage Disease) study was 
initiated in 1997. This ongoing and prospective study was designed to investigate 
urinary albumin excretion (UAE) as a predictor of cardiovascular and renal disease in 
the general population. Study details are described elsewhere.11 The PREVEND study 
was approved by the local medical ethics committee and was conducted in 
accordance with the guidelines of the Declaration of Helsinki. The PREVEND study is 
enriched for albuminuria. To create a representative sample of the general population, 
the enriched part (UAC>10 mg/L) was reweighed by proportionally taking an SPSS 
generated random subset (n=3432). Subjects with missing data on UAC and/or with 
leucocyturia, erytrocyturia and kidney disease were excluded. In the total PREVEND 
cohort, frozen urine samples for re-assessment of albumin concentrations were 
available from the 340 subjects that died during follow-up from 1997-1998 until 
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December 2004. This number of cases provided a power of 91% with an α of 0.05 for 
detection of a difference of 0.05 in area under the curve (AUC) of a receiver operating 
characteristic (ROC) curve. The dataset was therefore enriched with all subjects that 
died, resulting in a final study population of 3485 subjects.     
 
URINE SAMPLES 
Participants were asked to collect two 24 hour urine samples. They were asked to 
keep the collected urine stored in two 3 liter plastic containers at 4°C to a maximum 
of two days prior to the visit to the outpatient clinic. The volume of the urine was 
determined immediately after arrival of the subject to the clinic. For fresh 
determination of UAC, specimens were kept at 4°C in 10 ml polystyrene tubes. 
Samples were subjected to approximately 10 hand-inversions and centrifuged before 
analysis. A portion of both fresh 24 hour urine collections was stored in 2 ml 
polypropylene aliquots at -20°C in manual-defrost freezers. For assessment after 
prolonged frozen storage, specimens were obtained from storage one day before 
analysis, and thawed at 4°C. Again, specimens were subjected to hand-inversions and 
centrifuged for 4 minutes at 15,000xg.  
 
LABORATORY METHODS 
UAC was determined by immunonephelometry (Behring Nephelometer, Marburg, 
Germany) with a threshold of 2.4 mg/L. The variability encountered with calibration 
ranged between 1.6 and 4.4%, and the variability encountered with reagent lot 
changes ranged between 1.1 and 2.4%. The intra- and interassay coefficients of 
variation (CV), valuated in our laboratory, were 2.7 and 4.5%, respectively.    
MORTALITY DATA 
Total mortality was the endpoint of the study. The vital status of the participants was 
evaluated through the municipal register. Follow-up for survival was defined as the 
period from the date of the first visit at the first screening (1997-1998) until death or 
the 31st of December 2004. 422 subjects that were lost to follow-up were censored 
for the last available date. 
  
STATISTICAL ANALYSES 
Power calculations were performed using NCSS - Statistical and Power Analysis 
Software - PASS (NCSS, Kaysville, Utah, USA). Calculations to determine statistical 
significance between ROC curves were performed using AccuROC version 2.5 
software (Accumetric Corporation, Montreal, Canada). ROC curve analyses were 
performed to investigate the predictive value of urinary albumin excretion (UAE) 
determined from fresh and thawed samples for mortality. SPSS version 12 software 
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was used to perform further statistical analyses (SPSS, Chicago, IL, USA). To investigate 
whether prolonged frozen storage results in the introduction of an additional error, we 
used the opportunity that the participants in our study gathered two 24 hour urine 
collections. These two urine collections allowed us to calculate the intra-individual day-
to-day variation in albumin concentration for fresh urine samples and for urinary 
albumin assessment after prolonged frozen storage. Any difference between these 
coefficients of variation (CV) can solely be accounted for by frozen storage. The size 






Subjects were excluded if one or more of the assessed albumin concentrations was 
below the detection limit of 2.4 mg/L. A value of P<0.05 (two-sided) was used as the 




During a median follow-up time of 2388 days (maximum 2649 days) 340 subjects 
died. The median albumin concentration [interquartile range] in the fresh urine 
samples was 5.0 [3.3-8.6] mg/L. Table 1 shows the baseline characteristics of all 3485 
subjects. The median (interquartile range) UAC in fresh urine samples was 5.0 (3.3-8.6) 
mg/L. UACs were reassessed after a mean (SD) time period of 7 (0.4) years (range, 
7.7-8.8 y) of frozen storage. After frozen storage the mean (SD) change in albumin 
concentration was -27 ± 26% for samples with a fresh UAC of <10 mg/L, -51 ± 29% 
for 10-20 mg/L, -43 ± 30% for 20-200 mg/L, and -14 ± 17% for samples with a fresh 
UAC >200 mg/L (P<0.001).   
The between-day variations were 24%, 26%, 25%, and 16% for fresh samples 
(CVanalytical+biological), and 27%, 40%, 37%, and 23% for frozen samples (CVtotal) for the  
10, 10-20, 20-200, and  200 mg/L categories, respectively. Freezing, therefore, 
introduced an additional variation (CVfreezing) of 12%, 30%, 27%, and 17% in the 
respective categories. The overall additional measurement error (CVfreezing) resulting 
from frozen storage was 18% (CVanalytical+biological 25% and CVtotal 31%). ROC analysis 
revealed a mean (SE) area under the curve of 0.80 (0.014; P<0.001) for the prediction 
of mortality by UAC assessed from fresh samples and 0.74 (0.016; P<0.001) from 





Table 1. Baseline characteristics according to survival status. 
 Alive Dead P-value 
Subjects, N 3145 340  
Age, years 48 (12) 63 (10) <0.001 
Male gender, % 46 68 <0.001 
BMI, kg/m2 26 (4) 27 (4) NS 
Current smoking, % 31 41 <0.001 
Waist circumference, cm, M 93 (10) 98 (11) NS 
Waist, circumference, cm, F 82 (12) 89 (13) NS 
Systolic bloodpressure, mm Hg 126 (18) 142 (24) <0.05 
Diastolic bloodpressure, mm Hg 73 (9) 78 (10) <0.05 
Glucose, mmol/L 4.7 (1.0) 5.3 (1.3) <0.001 
Cholesterol, mmol/L 5.6 (1.1) 5.9 (1.1) NS 
Anti-hypertensive use, % 16 38 <0.001 
Lipid lowering therapy, % 5 12 <0.001 
Diabetes, % 1.0 6.2 <0.001 
UAE fresh samples, mg/24h 6.9 (5.4-10.4) 18.2 (9.4-54.5) <0.001 
UAE frozen samples, mg/24h 4.6 (3.5-6.3) 9.1 (4.9-33.5) <0.001 





Our study is, to the best of our knowledge, the first prospective report on a decrease 
in predictive properties of albuminuria for mortality after prolonged frozen storage of 
urine samples at -20°C. Our study is also the first to report on introduction of an 
additional measurement error by freezing, along with a decline in albumin 
concentrations. The effect of frozen storage on the measured albumin concentration 
in urine samples has been studied before, but only after storage for of up to two 
years.9,12 In the present study, with a duration of storage of 7 years, we found 
decreases of 27, 51, 43, and 14% after frozen storage at -20°C for samples with fresh 
concentrations <10, 10-20, 20-200, and >200 mg/L respectively. These values are all 
slightly higher than the corresponding decreases of 25, 30, 26 and 13% after 18-24 
months of storage in our previous study.6  
In that study, we found that there was a relatively rapid initial decline up to after 8 
months of storage, followed by relative stabilization. One of the most suggested 
explanations for lower albumin concentrations is the entrapment of albumin in a 
precipitate, containing proteins, phosphate and urea.8,10  


























Adhesion of albumin to the wall of storage tubes may also play a role.13 Thorough 
vortex-mixing or applying hand-inversions of the thawed urine samples before albumin 
analysis has been shown to prevent a considerable decline in albumin, but does not 
completely prevent it.6,14 Hydrolysis of albumin by bacterial proteases is another 
proposed reason for a decline in albumin after frozen storage.15 All these factors may 
play a role in the introduction of an additional measurement error along with a decline 
in assessed albumin concentrations. The introduction of an additional measurement 
error by freezing has been suggested before,5-10 but there are, to the best of our 
knowledge, no previous studies that actually made the comparison with fresh samples.  
A limitation of our study is that we did not specifically investigate subgroups of special 
interest, such as subjects with diabetes mellitus, renal disease, and proteinuria. One 
could argue that another limitation of our study is that we did not investigate the effect 
of storage of urine samples at -80°C. MacNeil et al. investigated the effect of storage 
for 22 weeks at -20°C and -70°C and found no significant difference in albumin 
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concentration during this time.5 These authors therefore suggested that storage at -
70°C is more optimal than storage at -20°C. Schulz et al. did not assess albumin 
concentrations in fresh samples, but only after frozen storage at -20°C and -70°C.4 
Albumin concentrations assessed from samples stored at -70°C were significantly 
higher than those assessed from samples stored at -20°C. It could, however, not be 
investigated whether storage at -70°C indeed prevents the occurrence of a decline or 
introduction of additional variation.  
Prolonged frozen storage and subsequent thawing causes albuminuria to become a 
less powerful predictor of mortality than if it were assessed from fresh urine samples. 
Assessment of urinary albumin concentrations from frozen samples results in the 
introduction of an additional measurement error and falsely low concentrations. These 
effects of frozen storage on assessment of urinary albumin concentrations are relevant 
for the interpretation and design of epidemiological studies, screening programs, and 
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Albuminuria, as assessed by immunochemical assays, is used as a predictor of events 
in many epidemiological studies and as an intermediate end-point in clinical trials. We 
have recently shown that frozen storage results in assessment of falsely low urinary 
concentrations of immunochemically reactive albumin (UAC), particularly in the 
reference and microalbuminuric range (UAC 0-200 mg/L).1 When samples were 
subjected to hand-inversions or vortex-mixing prior to assessment, UAC remained 
almost unchanged (2.6 to 5.3% decrease) after 3 to 5 months of storage, whereas the 
difference increased to approximately -25% if samples were stored for 18 to 24 
months. 
It has been suggested that urinary pH is a determinant of the decline associated with 
freezing, but to the best of our knowledge there is only one study that actually 
investigated this issue. In that study, Erman et al. found no association between urinary 
pH and changes in UAC after 7 days of storage at -20°C.2 We investigated whether 
urinary pH is a determinant of changes in UAC after storage at -20°C for 4 and 12 
months. 
Urine samples (UAC>5 and UCIA<200 mg/L, n=230) were collected by participants 
during the third screening (2004/2005) for the Prevention of REnal and Vascular ENd-
stage Disease (PREVEND) Study (www.PREVEND.org). pH was measured by Combur 
strips (pH range 5-9, expressed as integers). UAC was assessed by 
immunonephelometry (Dade Behring, Germany) in fresh urine samples and after 
frozen storage in polypropylene aliquots. Samples were subjected to hand-inversions 
and centrifuged prior to assessment. 
Median UAC (interquartile range) was 10.7 (7.3;51.3) mg/L in fresh samples at 
baseline. Urinary pH was 5 in 38%, 6 in 44%, 7 in 15%, and 8 in 3% of cases. After 4 
months of storage the change in UAC was -29 (-59;-8)% at pH 5, -20 (-56;2)% at pH 6, 
-10 (-48;2)% at pH 7, and -6 (-38;-5)% at pH 8 (P<0.001 for trend). The results for 12 
months of storage are shown in figure 1. We conclude that urinary pH affects the 
magnitude of decline in UAC assessed after frozen storage. The mechanism 
underlying this observation may involve increased aggregation and denaturation of 
albumin at relatively low pH, because of the isoelectric point of albumin at pH 4.7. 
One study has been performed in which urinary pH has been adjusted before storage 
at -20°C.3 In this study, pH was adjusted to 7, and the storage period was 8 weeks. 
Results were nevertheless promising: there was no significant decrease after 
adjustment of pH, while UCIA decreased significantly in unadjusted samples. 
Adjustment of pH may be a feasible option for better preservation of urine samples 
that are meant to be stored for prolonged time before assessment of albumin. 






















Figure 1. Change in UAC after 12 months of storage at -20°C according to pH by box-and-whiskers plot. 
The box indicates the lower and upper quartiles and the central line is the median. The whiskers represent 
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Urinary albumin detection by immunonephelometry is decreased by ~30% in samples 
that have been frozen at -20°C. An HPLC method for assessment of urinary albumin 
that detects immunochemically reactive and immunochemically nonreactive albumin 
has been introduced as an alternative to immunonephelometry. We investigated 
whether this technique is affected by sample temperature, particularly freezing.  
Urine samples (n=295) were collected from the general population (Prevention of 
REnal and Vascular End-Stage Disease Study). Samples were assessed fresh and after 
storage at -20°C for 4, 8, and 12 months and at -80°C for 12 months by both 
immunonephelometry and HPLC.  
With immunonephelometry, storage for 4, 8, and 12 months at -20°C resulted in 
mean (SD) urine albumin changes of -21% (29%), -28% (29%), and -34% (31%) 
(P<0.001 for trend). Storage at -80°C resulted in a 5% (19%) change after 12 months 
of storage (NS). With HPLC, storage for 4, 8, and 12 months at -20°C resulted in urine 
albumin changes of -33% (28%), 43% (24%), and 55% (21%) (P<0.001 versus 
immunonephelometry). Storage at -80°C resulted in a -29% (29%) change (P<0.001 
versus immunonephelometry).  
Loss of albumin after freezing urine depends not only on freezing temperature but 
also on detection method. Detection of albumin by immunonephelometry appears to 
be significantly less influenced by freezing than detection by HPLC. Storage at -80°C 
appears to prevent loss when using immunonephelometry, whereas HPLC still shows 
considerable loss even when urine is frozen at -80°C. We propose that for reliable 
measurement of urine albumin, fresh samples should be used. 




Urine albumin measurements are used in patient care and epidemiological studies 
and as intermediate endpoints in clinical trials. In the latter cases, urine samples are 
often stored frozen before assessment for practical reasons and for prevention of 
analytical day-to-day variation and drift. We recently showed that 1 year of frozen 
storage of urine at -20°C results in a ~30% decrease in albumin concentrations, as 
well as an increase in the measurement error, in particular in samples with initial 
concentrations in the normoalbuminuric and microalbuminuric ranges.1,2 Importantly, 
this change in urinary albumin concentrations induced by frozen storage resulted in a 
significant decrease in predictive properties of urine albumin for mortality.2 The 
decrease of albumin concentrations during frozen storage of urine has been attributed 
to several potential causes. One of those is the freezing temperature at which frozen 
samples are stored. The effect of frozen storage has mainly been studied in urine 
samples stored at -20°C; only a few studies have investigated frozen storage at lower 
temperatures. Results of 2 studies suggest that frozen storage at -70°C is superior to 
storage at -20°C.3,4 Interpretation of these studies, however, is hampered by the fact 
that 1 did not include fresh assessments5 and the other did not find a significant 
difference between -70°C and -20°C, possibly owing to lack of power.3 A possibility 
that has not been studied to date is a potential effect of measurement technique. The 
current methods of measuring urine albumin are based on immunochemical 
techniques. It is conceivable that prolonged freezing changes the immunoreactivity of 
the albumin molecule (thus resulting in an apparent decrease in albumin 
concentrations).3,6 Recently, a new method for assessment of urine albumin has been 
introduced. It detects immunochemically nonreactive albumin in addition to the 
immunochemically reactive albumin detected by conventional assays.7 It is not known 
whether and to what extent frozen storage affects urine albumin assessed by HPLC. 
We compared the effect of prolonged frozen storage at -20°C on urinary albumin 
assessed by HPLC and an immunochemical assay (immunonephelometry) and 




MATERIALS AND METHODS 
URINE SAMPLES 
Urine samples were collected from consecutive individuals visiting our outpatient 
clinic for the 3rd screening of the ongoing Prevention of REnal and Vascular ENd-
Stage Disease (PREVEND) study (2004-2005).8 Participants collected 24 hour urine 




before the visit to the outpatient clinic. For fresh determination of urinary albumin 
concentration (UAC) by immunonephelometry and HPLC, samples were kept at 4°C 
in polystyrene tubes for a maximum of 3 days. The maximum of refrigerated storage 
time for a fresh specimen would therefore be 5 days. Samples with a fresh 
concentration of immunochemically reactive albumin <5 mg/L were excluded to 
ensure potential detection of decrease with storage, given the lower detection limit of 
the assay of 2.4 mg/L. Samples with a fresh UAC of >200 mg/L were also excluded 
because the major differences between the 2 methods lie in the microalbuminuric 
and reference range. Portions of fresh urine were stored in polypropylene vials for 
assessment after storage for 4, 8, and 12 months at -20°C (n=295) and after 12 
months at -80°C in a subset of these samples (n=224). All samples were subjected to 
hand-inversions and centrifuging before assessment. 
 
LABORATORY METHODS 
We measured immunochemically reactive albumin by use of immunonephelometry 
(Dade Behring Diagnostics). The intra-assay and between-day CVs were 2.7% and 
4.5%, respectively. The variability in control and reagent lot changes was 1.1% to 
3.5% and 1.1% to 2.1%, respectively. HPLC UAC was measured using an 
Agilent/Hewlett Packard 1100 HPLC with a limit of quantification of 3.0 mg/L. The 
intra-assay and between-day CVs were 5.6% and 2.4%, respectively. Aliquots of urine 
(25 μL) were injected onto a Zorbax Bio series preparative GF 250 column (9.4 mm 
ID by 25 mm). The mobile phase was phosphate-buffered saline (9 g/L NaCl, 0.775 
g/L Na2HPO4, 0.165 g/L KH2PO4, pH 7.4) run at a flow of 0.5 mL/min. Peak 
integration was performed by use of the manufacturer-specified drop-line method 
(Accumin®). 
We measured urine pH was measured by use of Combur test strips (Roche), which 
have a measurement interval from pH 5 to 9; results are expressed as integers. We 
measured urinary creatinine by use of MEGA (Merck). 
 
STATISTICAL ANALYSES 
We performed statistical analyses by use of SPSS 14.0. Data are presented as mean 
(SD) percentage changes in albumin, which had a Gaussian distribution. Skewed data 
are presented as median (interquartile range). We performed repeated measures 
analyses (MANOVA) to test differences between different time points for frozen 
storage at -20°C. We performed correlation analyses according to Pearson, with log-
transformation of variables with a skewed distribution. We analyzed differences 
between immunonephelometry and HPLC by use of paired-samples t-tests at the 
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different time points and freezing conditions. Differences from zero were tested by 1-




We used urine samples from 295 individuals. Mean (SD) age was 55 (12) years, 56% 
were males, BMI was 28 (4) kg/m2, and 5.9% had diabetes. Median (interquartile 
range) fresh urine albumin assessed by immunonephelometry was significantly lower 
than by HPLC [11 (7-51) mg/L vs 55 (34-111) mg/L, P<0.001]. After 4 months of 
storage at -20°C, the change in immunochemically reactive urine albumin was -21% 
(29%) (P<0.001 for difference with zero change). The change was -28% (29%) after 8 
months and -34% (31%) after 12 months (P<0.001 for trend) (figure 1). When 
measuring urine albumin that was stored at -80°C for 1 year, no change in albumin 
concentrations was observed [5% (19%), NS]. Measurement of urine albumin by 
HPLC after frozen storage at -20°C resulted in significantly higher changes (P<0.001 
for comparison of all time-points with immunonephelometry) of -33% (28%) at 4 
months (P<0.001 for difference from zero change), -43% (24%) at 8 months, and -
55% (21%) at 12 months (P<0.001 for trend). Storage at -80°C did not prevent the 
decrease [-29% (29%), P<0.001]. Scatterplots of values before and after 12 months of 
storage are presented in figure 2. With storage at -20°C and assessment by 
immunonephelometry (figure 2a), there was substantial variation in the stability of 
individual specimens, in particular at low albumin concentrations. Despite exclusion 
of samples with a fresh concentration <5 mg/L, and lower limit of detection 2.4 mg/L, 
a substantial amount of samples with low fresh concentrations presented with 
concentrations at or below the detection limit after frozen storage for 12 months. 
With storage at -80°C and assessment by immunonephelometry (figure 2b), there 
were no decreases to below the detection limit, and variation in stability was much 
less, in particular in the lower range of concentrations. With storage at -20°C and 
assessment by HPLC (figure 2c), losses were more notable than with storage at -20°C 
and assessment by immunonephelometry, in particular in the higher range of 
concentrations. Variation in stability of individual specimens was largest in the lower 
range of concentrations. With storage at -80°C and assessment by HPLC (figure 2d), 
losses were smaller over the whole range of concentrations, but considerable 
variation in stability of individual samples remained. Given the large variation in 
stability between specimens, we subsequently investigated whether percentage 
change in concentrations after frozen storage is associated with other factors, such as 
pH, urine creatinine concentrations, and fresh urine albumin concentrations. Urinary 


















Figure 1. Percentage change in albumin at -20°C and -80°C assessed by immunonephelometry and HPLC 
respectively. Data are presented as mean (SD) percentage difference in UAC. 
 
 
The mean urine creatinine concentration was 9.6 (4.6) mmol/L. Respective 
correlations for pH, urine creatinine, and log-transformed fresh albumin with 
percentage change after 12 months of storage at -20°C were r=0.26 (P<0.001), r=-
0.22 (P=0.001), and r=0.33 (P<0.001) for immunonephelometry and r=0.13 (P=0.05), 
r=0.01 (P=0.90), and r=-0.05 (P=0.44) for HPLC. Respective correlations with 
percentage change after 12 months of storage at -80°C were r=0.22 (P=0.001), r=0.01 
(P=0.86), and r=-0.16 (P=0.02) for immunonephelometry and r=0.05 (P=0.42), r=-0.04 
(P=0.58), and r=-0.41 (P<0.001) for HPLC. Because decreases in urine albumin 
concentrations are represented by negative percentages, positive correlations indicate 
that with increasing values of pH, urine creatinine, and log-transformed fresh albumin, 
decreases become smaller, and vice versa for negative correlations. 
Representative HPLC chromatograms before and after storage up to 12 months at        
-20°C and for 12 months at -80°C are shown in figure 3. One specimen with a fresh 
HPLC albumin concentration of 31.9 mg/L decreased to assessed concentrations of 
9.9 mg/L, 8.3 mg/L, and 9.1 mg/L after 4, 8, and 12 months of storage at -20°C 
respectively (figure 3a-d). After 12 months of frozen storage at -80°C, the assessed 
concentration was 30.0 mg/L (figure 3e). For this specimen, the concentration 
assessed by immunonephelometry was 5.6 mg/L. Results for another specimen, with a 
fresh HPLC albumin concentration of 55.0 mg/L, are shown in figure 3f-j. For this 
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Figure 2. Scatterplots of albumin concentrations before and after 12 months of storage at -20°C and        
-80°C for assessment by immunonephelometry and HPLC respectively.    
 
 
For both specimens, fresh chromatographic patterns and after storage at -80°C for 12 
months were very similar (figure 3a versus 3e and 3f versus 3j). Some extra fractions 
appeared after 4 months of storage in the sample with a fresh HPLC concentration of 
31.9 mg/L (figure 3b), which became less prominent with longer frozen storage 
(figure 3c and 3d). Appearance of extra fractions was less pronounced in the other 
specimen (figure 3g). 
 
 


















































































































































































































































































































Figure 3. Representative HPLC chromatograms of two albumin samples assessed before and after 4, 8, 
































A. Example 1: UAC (31.9 mg/L) fresh urine. 
B. Example 1: UAC (9.9 mg/L) after 4 months of storage at -20°C.  
C. Example 1: UAC (8.3 mg/L) after 8 months of storage at -20°C.  
D. Example 1: UAC (9.1 mg/L) after 12 months of storage at -20°C.  










































F. Example 2: UAC (55.0 mg/L) fresh urine. 
G. Example 2: UAC (11.3 mg/L) after 4 months of storage at -20°C.  
H. Example 2: UAC (6.7 mg/L) after 8 months of storage at -20°C.  
I. Example 2: UAC (5.2 mg/L) after 12 months of storage at -20°C. 










We found greater susceptibility to the negative effects of frozen storage on urine 
albumin assessed by HPLC than by immunonephelometry. We also found that storage 
at -80°C can prevent the decline that occurs with 1 year of storage at -20°C if samples 
are assessed by immunonephelometry, but not by HPLC. We also found considerable 
variation in declines between samples and significant correlations of these declines 
with urinary pH, urinary creatinine concentrations, and fresh albumin concentrations.  
Our study is the first to investigate the effect of prolonged frozen storage on urine 
albumin assessed by HPLC. One study that investigated a maximum of 2 months of 
storage reported no change in measured albumin concentrations.7 Neither data nor 
baseline albumin were presented, however, so the power of that study for detecting 
changes cannot be estimated, in particular because the change in albumin 
concentration associated with freezing is time-dependent, highly variable between 
individuals, and dependent on the initial concentrations.1,2 Our study shows that at 
least after 4 months of frozen storage and beyond, there is a profound effect on 
urinary albumin concentrations assessed by HPLC. 
The results of our study are relevant not only to the interpretation of individual studies 
that use frozen samples of urine for albumin measurement, but also to the 
interpretation of previous studies that compare urine albumin assessed by HPLC with 
immunochemical methods.6,7,9-15 All studies to date used urine samples that had been 
stored for varying durations of time at -20°C or -70°C/-80°C before assessment of 
urine albumin by HPLC. In some of these studies, immunochemically reactive albumin 
was assessed from fresh samples,9,12,16,17 whereas others used frozen samples.6,11,13,14 In 
a previous study in which we compared nephelometric values from fresh samples 
with HPLC values from frozen samples, we found for the normoalbuminuric range 
that urine albumin assessed by HPLC is a factor of 3 higher than urine albumin 
assessed by immunonephelometry, and a factor of 1.3 higher in the microalbuminuric 
range.9 In the present study, we found a factor of 5 difference between HPLC and 
immunonephelometry over this concentration range as a whole if both assessments 
were performed in fresh samples. Relevant comparisons can therefore only be made if 
both assays have been performed in fresh samples. Because of the greater effect of 
frozen storage, it is likely that the use of HPLC measurement of frozen samples will 
lead to more underestimation (compared to classic methods) both in terms of 
prevalence of microalbuminuria and as a predictor of events.   
We found positive correlations between urinary pH and percentage change in 
albumin concentrations after 12 months of storage at -20°C and -80°C for assessment 
by immunonephelometry, and a borderline significant correlation for assessment by 
HPLC after 12 months of storage at -80°C. These correlations indicate smaller 
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decreases at higher values of pH. The mechanism underlying this observation may 
involve increased aggregation and/or denaturation of albumin at relatively low pH, 
because of the isoelectric point of albumin at pH 4.7. The 1st of the 2 series of 
representative HPLC chromatograms showed appearance of early peaks and 
disappearance of the albumin peak after 4 months of storage at -20°C (figure 3b). This 
is likely to be the consequence of aggregation of albumin molecules, and possibly of 
other proteins. The later disappearance of these peaks after 8 and 12 months of 
storage could be consistent with degradation. We also found a significant inverse 
correlation between urine creatinine concentrations and percentage change in 
albumin concentration after 12 months of storage, but only for storage at -20°C and 
assessment by immunonephelometry. This is consistent with greater decreases in 
concentrations in more concentrated urine samples. Correlations of percentage 
changes in albumin concentrations with fresh albumin concentrations are consistent 
with relatively small percentage decreases in samples with high fresh albumin 
concentrations for assessment by immunonephelometry and storage at -20°C, 
whereas opposite correlations were present for assessment by immunonephelometry 
and storage at -80°C and for assessment by HPLC and storage at -80°C. The opposite 
correlations for assessment by immunonephelometry between storage at -20°C and     
-80°C may be explained by the fact that aggregation is prevented to a large extent 
with storage at -80°C for almost all samples, with the significant correlation for the 
greater part being the consequence of some samples in which declines in assessed 
albumin concentrations occurred.  
For this study, we used for HPLC the routine commercially available method 
(Accumin®, AusAm Biotechnologies), which makes use of drop-line integration. 
Recently, the accuracy of the HPLC assay and the integration method has been under 
debate. Sviridov et al.18 showed by use of mass spectrometry that the size exclusion–
based HPLC method is incapable of completely resolving the albumin molecule from 
other proteins in the urine. The authors found that the peak indicated as albumin 
contained up to 20% other proteins such as transferrin, α1-proteinase inhibitor, and 
α1-acid glycoprotein. Further studies will be needed to investigate the content of the 
peak and the outcome of potential different integration methods such as through-to-
through basis.  
 
We did not further study the reason for the greater sensitivity of HPLC measurement 
to the effects of prolonged freezing. One potential explanation might be that the 
additional albumin molecules that are measured by HPLC are more susceptible to loss 
with frozen storage. As far as the effect of different urine freezing temperatures on 




fresh assessments in 1 study and low numbers of samples in another.3,5 Our study is 
the first to substantiate that storage at -80°C is indeed better than storage at -20°C, in 
particular if it concerns assessment of urine albumin. However, this only applies when 
albumin is measured with immunonephelometry (and much less to HPLC).  
 
In conclusion, the decrease of albumin concentrations after freezing urine for a 
prolonged time period depends not only on the freezing temperature but also on the 
detection method. Detection of albumin by immunonephelometry appears to be 
significantly less influenced by freezing compared with HPLC. Storage at -80°C 
appears to prevent loss when using immunonephelometry, whereas HPLC detection 
still shows considerable loss even when urine is frozen at -80°C. We propose that for 
reliable measurement of urine albumin, fresh samples should be used, particularly in 
the normo- and microalbuminuric range. Previous urine albumin data (and studies) 
obtained with frozen samples should be interpreted with extreme caution. 
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Albuminuria has recently drawn much attention as a valuable risk marker for 
cardiovascular and renal disease progression. Albuminuria can be measured and 
expressed in two ways: 1) in a spot morning urine sample as urinary albumin 
concentration (mg/liter) or albumin:creatinine ratio (mg/mmol) and 2) in a 24 hour 
urine collection as urinary albumin excretion (mg/24 hour). It has not yet been 
clarified which measure for albuminuria is preferable in clinical practice. One of the 
points on which a choice should be made is which measure shows the least within-
person coefficient of variation. From the perspective of our work in the Prevention of 
REnal and Vascular ENdstage Disease Intervention Trial, 1997-2001, we discuss several 
methodological issues that are important when interpreting studies on this topic. It is 
argued that fresh urine should be used, since freezing at -20°C results in considerable 
extra variability in the albumin concentration. Furthermore, it is important to use 
specifically collected urine samples and not portions of a 24 hour urine sample as a 
surrogate for a spot morning urine sample. Albuminuria follows a circadian rhythm. 
Consequently, values for the within-person coefficient of variation will therefore be 
different when they are measured in a portion of a 24 hour urine collection in 
comparison with a spot morning urine sample. 
 
 




Albuminuria has recently drawn much attention as a marker for cardiovascular and 
renal disease progression.1-4 The amount of albumin excreted in urine over a 24 hour 
period is considered the ‘gold standard’ for defining albuminuria. However, collecting 
urine over 24 hours is a cumbersome procedure for most subjects. Therefore, often 
untimed random specimens are used. In these samples, the urinary albumin 
concentration can be taken as an alternative for defining albuminuria. Unfortunately, 
the urinary albumin concentration is dependent on hydration status. When a subject is 
well hydrated, the urinary albumin concentration will be low because of dilution and 
vice versa, whereas the 24 hour excretion of albumin would not have been influenced. 
Another option uses the albumin:creatinine ratio, which ‘corrects’ for dilution or 
concentration by taking the urinary creatinine concentration into account. The 
purpose of a recent study by Dyer et al.5 was to assess the strengths and weaknesses 
of the urinary albumin:creatinine ratio and the albumin concentration as alternatives to 
albumin excretion. However, their study has a number of limitations. First, they found 
that the within-person median coefficients of variation for urinary albumin 
concentration, albumin:creatinine ratio, and albumin excretion are approximately 30-
80%, with the coefficient of variation for urinary albumin concentration, on average, 1-
5% lower than the coefficient of variation of the other two measures.5 The problem 
here is that the coefficients of variation for all the variables are so high that they in fact 
disqualify the use of urinary albumin measures as a reliable risk marker for future 
cardiovascular events. However, it may well be that these coefficients of variation for 
the various albumin measures are unrealistically high. Samples had been frozen at -
20°C for approximately 3 years before being analyzed.  
As Dyer et al.5 themselves caution, this may have affected the within-person coefficient 
of variation. In our experience, long-term freezing at -20°C results in falsely low urinary 
albumin concentrations, especially when thawed samples are not hand- inverted or 
vortex mixed before assessment.6 Unfortunately, information on pre-assessment 
sample handling is lacking in this study.5 More importantly, we also found that even 
short-term freezing induced considerable variability for albumin measurements6 but 
less for creatinine. Others have also observed an increase in the variability of the 
albumin concentration when assessment takes place after freezing at -20°C.7-10 The 
fact that the two 24 hour urine collections in the study of Dyer et al.5 were collected at 
a specific point in time, being 3-6 weeks apart, may have influenced results. It may 
well be that the coefficient of variability for the various measures of urinary albumin 
excretion varies over time and that the variation over time is different for the various 




results from the Prevention of REnal and Vascular ENdstage Disease Intervention Trial 




In this double-blind intervention study, 864 subjects with persistent high-normal or 
microalbuminuria were selected at random according to a 2-3-2 factorial design to 
fosinopril/placebo and to pravastatin/placebo. Persistent high-normal or 
microalbuminuria was defined as a urinary albumin concentration greater than 10 
mg/liter in a spot morning urine sample (first morning void) and a mean urinary 
albumin excretion of 15-300 mg/24 hours in two subsequent 24 hour urine samples. 
Other inclusion criteria were the following: blood pressure less than 160/100 mm Hg, 
no use of antihypertensives, total cholesterol less than 8.0 mmol/liter (or <5.0 
mmol/liter in the case of a previous myocardial infarction), and no use of lipid-
lowering medication. We used the data of all 216 subjects receiving placebo-placebo, 
since with these subjects the coefficient of variation of albumin measures could be 
ascertained without the interfering influence of medication. These subjects collected 
24 hour urine samples at day 1, day 2, and months 3, 6, and 15. Albumin was 
measured in fresh urine by immunonephelometry (Dade Behring Diagnostics, 
Marburg, Germany). The intra- and interassay coefficients of variation were 2.7 
percent and 4.5%, respectively, and creatinine was measured by dry chemistry 
(Eastman Kodak, Rochester, New York, USA), with intra- and interassay coefficients of 
variation of 0.9% and 2.9%, respectively. Intra-individual variability in albumin 
excretion was assessed by means of the within-person coefficient of variation, which is 
calculated from multiple measurements made from the same individual as 100 x 
standard deviation/mean.  
To estimate the daily variability for each urinary albumin measure, we calculated each 
individual’s coefficient of variation for the first collection and the repeat collection and 
then used the median values among participants to summarize daily within-person 
variability. This procedure was chosen in analogy with the study by Dyer et al.5  
 
 
RESULTS AND DISCUSSION 
The baseline characteristics of the subjects under study were as follows: age, 49 
(standard deviation (SD): 11) years; male, 59%; systolic blood pressure, 127 (15) 
mmHg; diastolic blood pressure, 74 (9) mm Hg; total cholesterol, 5.6 (1.0) mmol/liter; 
glucose, 4.9 (1.0) mmol/liter; diabetes mellitus, 3.3 percent; serum creatinine, 83 ( 13) 
μmol/liter; and albuminuria, 22.5 (range: 8.6-125.7) mg/24 hour.   
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Table 1. Within-person coefficient of variation over time for various urinary albumin measures, 
Prevention of Renal and Vascular ENdstage Disease Intervention Trial, 1997–2001.  
 
 
Results are shown in table 1. These data show that the within-person coefficients of 
variation of all albumin measurements are considerably less than the values obtained 
by Dyer et al.5 This may, of course, be due to differences between the subjects 
included or the techniques applied. However, we hypothesize that the fact that we 
measured albumin and creatinine in fresh urine (instead of in urine that has been 
frozen at -20°C) is more important. Of course, it is logistically difficult to conduct 
epidemiologic studies on fresh urine samples. It might be that storage at -80°C will be 
suitable, as suggested by Schultz et al.7 However, these latter data need confirmation. 
In our experience, the assay measuring urinary albumin concentration performs worse 
than the two other measures. Furthermore, our data show that the within-person 
coefficient of variation is time dependent. When two urine samples are collected 
within a short period, the within-person coefficient of variation is superior to when the 
time between two urine collections is longer. This information is important for the 
correct interpretation of comparisons between studies reporting on coefficients of 
variation for the various albumin measures. Second, the conclusions by Dyer et al.5 are 
based on a comparison of the urinary albumin concentration and the 
albumin:creatinine ratio in relation to a reference standard (i.e., 24 hour albumin 
excretion). In daily practice, the urinary albumin concentration and the 
albumin:creatinine ratio are assessed from spot morning urine samples. However, in 
the study by Dyer et al.,5 the same 24 hour urine sample was used for all 
measurements. It is generally acknowledged that urinary albumin and creatinine 
excretions follow a circadian rhythm.12,13 This rhythm is dependent on posture, 
exercise, and dietary factors, such as protein intake, fluid intake, and so on. This is not 
a theoretical issue.     
In the Prevention of Renal and Vascular ENdstage Disease Intervention Trial, subjects 
collected a spot morning urine sample (first morning void) 3 months before entering 
the trial. In this sample, the urinary albumin concentration was 18.2 mg/liter, the 
urinary creatinine concentration was 12.3 mmol/liter, and the albumin:creatinine ratio 
 Median within-person coefficient of variation (%) comparing 
day 1 with one of the following 
 Day 2 Month 3 Month 6 Month 15 
Urinary albumin concentration (mg/liter) 19.2 26.6 26.0 27.1 
Albumin:creatinine ratio (mg/mmol) 13.8 17.7 21.7 23.8 




was 1.64 mg/mmol. These values differ considerably from the results obtained in the 
subsequent 24 hour urine collections, particularly with regard to the urinary creatinine 
concentration (8.7 mmol/liter; P<0.001 for comparison with the spot morning sample) 
and the albumin:creatinine ratio (1.91 mg/mmol; P<0.001), and less for the urinary 
albumin concentration (17.4 mg/liter; P=0.03). This phenomenon is likely to be of 
importance. It is to be expected that values for the within-person coefficient of 
variation will be quite different when they are measured from spot morning urine 
samples instead of 24 hour urine collections. It is also to be expected that the urinary 
albumin concentration and especially the albumin:creatinine ratio cutoff values 
indicating microalbuminuria will be different when these variables are measured in a 
spot morning sample instead of a 24 hour urine collection. Of course, we fully 




Carefully designed prospective studies should be performed to clarify the issue of 
which urinary albumin measure to use in patient care and in epidemiologic studies.  
In such studies, urinary albumin and creatinine should be measured preferably in fresh 
urine. Another option may be to measure in urine that has been stored at -80°C. When 
interpreting studies on which urinary albumin method to use, investigators should take 
into account the time dependency of the within-person coefficient of variation for the 
various albumin methods. Finally, portions of a 24 hour urine collection should not be 
used as a surrogate for an untimed random sample. Until such data are available and 
confirmed, the 24 hour urinary albumin excretion should in our opinion remain the 
gold standard.  
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Microalbuminuria has recently been identified as an independent risk factor for 
cardiovascular disease in the general population. Immunochemical urinary albumin 
assays only detect immunochemically reactive intact albumin. High Performance 
Liquid Chromatography (HPLC) is able to detect both immunochemically reactive and 
immunochemically nonreactive intact albumin. We compared both measurement 
methods respectively in subjects with normo-, micro- and macroalbuminuria in the 
general population.   
We used 24 hour urine samples that were collected within the framework of the 
second screening for the PREVEND study, a prospective cohort study on albuminuria 
in the city of Groningen, The Netherlands.  
With immunonephelometry as the immunochemical reference method, we classified 
986 subjects as normoalbuminuric, 283 as microalbuminuric, and 43 subjects as 
macroalbuminuric. The mean (SD) albumin concentration was 6.8 (4.3) mg/L for 
immunonephelometry in the urine samples of the 998 subjects with a concentration 
<20 mg/L according to immunonephelometry versus 17.6 (10.3) mg/L for HPLC 
(P<0.001, HPLC 159% higher). These values were 58.9 (40.6) mg/L for 
immunonephelometry versus 74.0 (51.8) mg/L for HPLC (P<0.001, n=280, HPLC 26% 
higher) in the concentration range between 20 to 200 mg/L and 436.3 (371.8) mg/L 
for immunonephelometry versus 399.1 (329.2) mg/L for HPLC above 200 mg/L 
(P=0.048, n=34, HPLC 8.5% lower). Associations of 24 hour urinary albumin excretion 
with cardiovascular risk factors were generally somewhat stronger for 
immunonephelometry than for HPLC. Logistic regression analyses with an abnormal 
ankle-brachial index as outcome parameter revealed adjusted odds ratios of 1.78 (95% 
CI 1.01-3.12, P<0.05) and 4.67 (95% CI 1.68-12.9, P<0.05) respectively for micro- and 
macroalbuminuria as determined by HPLC, compared to 1.37 (95% CI 0.77-2.41, 
P=NS) and 3.85 (95% CI 1.53-9.67, P<0.05) respectively for immunonephelometry. 
The ROC-curve showed similar sensitivity and specificity for both methods (P=0.25). 
The use of HPLC for the determination of urinary albumin concentrations reveals 
higher values compared to immunonephelometry, especially in the lower 
concentration range, resulting in a higher prevalence of microalbuminuria. With HPLC, 
compared to immunonephelometry, we found a 21% higher independent odds ratio 
for microalbuminuria with the presence of peripheral vascular disease, and a 30% 
higher independent odds ratio for macroalbuminuria. This higher prevalence of 
microalbuminuria accompanied with a similar absolute risk for peripheral vascular 
disease as compared to patients with microalbuminuria detected by 
immunonephelometry, suggests HPLC to identify more people at risk which is of great 
importance, especially where screening in large populations is concerned.  
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INTRODUCTION 
Microalbuminuria is widely established as one of the earliest indicators of incipient 
nephropathy in patients with type 1 and type 2 diabetes mellitus.1-6  
Early treatment, guided by annual microalbuminuria testing, has been shown to slow 
or even prevent progression to persistent albuminuria/proteinuria and end-state renal 
disease.7,8 Less well established, but certainly not of lesser importance, is the fact that 
albuminuria can be used to identify subjects at an increased risk of cardiovascular 
disease. This was first recognized in patients with type 2 diabetes mellitus,6,9,10 and 
later extended to patients with type 1 diabetes mellitus.11-14 Importantly, however, 
recent studies indicate that the risk for cardiovascular disease held by 
microalbuminuria is also present in the general population.15-19 From these studies it 
became not only apparent that microalbuminuria is very common in the general 
population, with a prevalence of 6.6% even in subjects without diabetes or 
hypertension,18 but also that it is an independent cardiovascular risk factor, even in 
subjects with a high normal urinary albumin excretion.19 Given the high global 
incidence of cardiovascular disease and the availability of adequate preventive 
treatment modalities, it is of great importance to identify those people at increased risk 
of cardiovascular disease as soon, and as adequate as possible. A reliable urinary 
albumin assay is obviously of great importance. 
Urinary albumin concentrations are traditionally measured using immunochemical 
methods, such as radioimmunoassay, immunoturbidimetry, and immunonephelometry. 
The limitation of these assays is that they can only detect albumin when 
immunochemically reactive. Recently, it has been discovered that diabetic rats excrete 
appreciable amounts of immunochemically nonreactive intact albumin besides 
immunochemically reactive intact albumin.20 The presence of immunochemically 
unreactive intact albumin has also been demonstrated in urine from diabetic patients 
using high-performance liquid chromatography (HPLC),21 a method which is capable 
of measuring both immunochemically reactive intact albumin and immunochemically 
nonreactive intact albumin.22  
We compared, in the general population, urinary albumin excretion as assessed by a 
conventional immunochemical method (immunonephelometry) with HPLC. To do so, 
we not only compared the prevalence of micro- and macroalbuminuria indicated by 
the different methods, but we also investigated associations of urinary albumin 
excretion as determined by the two methods with other cardiovascular risk factors and 






STUDY POPULATION AND DESIGN 
This study is part of the ongoing PREVEND study (Prevention of REnal and Vascular 
ENd stage Disease), running in the city of Groningen, the Netherlands. Details of the 
study design and the first screening are described elsewhere.23 Four years after the first 
screening, the study participants were invited for a second screening consisting of two 
visits. A total number of 6981 out of the original 8592 subjects visited our outpatient 
clinic between June 2001 and December 2003. Prior to the visits subjects were asked 
to fill out a questionnaire regarding, amongst others, drug use. Height, weight and 
waist circumferences were measured. During both visits, systolic and diastolic blood 
pressure were measured (Dynamap XL Model 9300 series device) at the right brachial 
artery (ten times in total). Within the first 5 minutes, systolic blood pressure at each leg 
was measured. Subjects were again asked to collect two 24 hour urine samples. They 
received oral and written instructions on how to collect 24 hour urine samples, and 
were asked to postpone urine collections in case of urinary tract infection or 
menstruation and to refrain from alcohol, smoking and heavy exercise during 
collection as much as possible. Fasting blood samples were drawn for determination 
of glucose, serum creatinine, total cholesterol and HDL-cholesterol. Blood pressure 
was again measured during this visit. We consecutively selected 1484 subjects (2968 
urine samples) from the PREVEND population which we enriched with micro- and 
macroalbuminuria. We assessed urinary albumin concentrations by 
immunonephelometry and HPLC.   
 
DATA HANDLING AND DEFINITIONS 
We excluded 172 subjects with either leucocyturia and/or erytrocyturia. For analytical 
comparison of both methods we composed groups consisting of a urinary albumin 
concentration of less than 20 mg/L, 20-200 mg/L and more than 200 mg/L.24 Analyses 
of associations with risk factors and markers of atherosclerosis were performed using 
categories based on urinary albumin excretion rates (below 30 mg/24 hour, 30-300 
mg/24 hour and above 300 mg/24 hour).25 Both analyses were performed using 
immunonephelometry as the reference method.  
Body mass index (BMI) was calculated by the ratio of weight and the square height. 
Obesity was defined as a BMI of >30 kg/m2. Systolic and diastolic blood pressure were 
calculated as the average of the last two measurements of both visits. Hypertension 
was defined as systolic blood pressure >140 mm Hg or diastolic blood pressure of >90 
mm Hg or the use of antihypertensive medication. The ankle-brachial index (ABI) was 
calculated as the ratio of the systolic blood pressure of the ankle of each leg and right 
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arm. The lowest ankle-brachial index was used in the analysis. Peripheral artery disease 
was defined as an ankle-brachial index <0.9.26 
 
LABORATORY METHODS 
Urinary immunochemically reactive albumin was measured by immunonephelometry 
(Behring Nephelometer using reagents from Dade Behring Diagnostics, Marburg, 
Germany) with a threshold of 1.8-2.3 mg/L and intra and interassay coefficients of 
variation of less than 2.2 and 2.6 %, respectively. Total urinary intact albumin 
(immunochemically reactive plus immunochemically nonreactive) was measured using 
an Agilent/Hewlett Packard 1100 HP series based on size-exclusion HPLC. Aliquots of 
urine (25 μl) were injected onto a Zorbax Bio series preparative GF 250 column (9.4-
mm I.D. x 25 mm). The mobile phase was phosphate buffered saline (PBS) run at a 
flow rate of 0.5 ml/min. Blood glucose was determined by ECA 180 (Depex, Houten, 
The Netherlands). Serum and urinary creatinine and serum total cholesterol and HDL-
cholesterol were determined by MEGA (Merck, Darmstadt, Germany). Urinary 
leukocyte and erythrocyte measurements were done by Nephur-test sticks (Boehringer 
Mannheim, Mannheim, Germany).  
 
STATISTICAL ANALYSIS 
Analyses were performed using SPSS 10.0 (SPSS, Chicago, IL, USA). The significance 
level was determined at P<0.05. Continuous data were reported as mean and standard 
deviation. Skewed distributions were expressed as median with interquartile range. 
Analytical comparison of both methods was performed using linear regression and 
limit of agreement method by Bland and Altman. For comparison between 
prevalence’s, chi-square analysis was carried out. Continuous data with a skewed 
distribution were transformed towards a normal distribution by log transformation. For 
urinary albumin excretion we applied log transformation to normalize the distribution. 
Mean values of continuous data were compared between groups by analysis of 
variance (ANOVA) or paired t-test (for comparison between urinary albumin 
concentrations by immunonephelometry and HPLC). To study the association of 
urinary albumin excretion as assessed by immunonephelometry and HPLC with 
cardiovascular risk factors and markers of atherosclerosis we used Pearson’s 
correlation analyses. We used logistic regression to study the association between 
albuminuria classes with diminished ABI. After analyzing crude odds ratios, 
adjustments were made for age and gender. In a subsequent model we additionally 
adjusted for BMI, glucose, systolic and diastolic blood pressure, use of 
antihypertensive drugs, serum total cholesterol, HDL-cholesterol, lipid-lowering therapy 
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and smoking. ROC curves were used to compare urinary albumin assessed by 





The characteristics of the subjects described for the various UAE groups as measured 
by immunonephelometry are shown in table 1. The results are consistent with an 
increased prevalence of cardiovascular risk factors in subjects with either micro- or 
macroalbuminuria. Only smoking was less prevalent in the macroalbuminuric subjects. 
Urinary albumin excretions were remarkably higher in the normo and 
microalbuminuria subjects when measured by HPLC compared to 
immunonephelometry. Of special note is the high prevalence of an abnormal ABI in 
subjects with micro- and macroalbuminuria compared to normo-albuminuric subjects 
(14.0% and 28.6% resp. vs. 6.7%).  
 
COMPARISON BETWEEN IMMUNONEPHELOMETRY AND HPLC 
Figure 1 shows a Bland and Altman bias plot for both assays. Data were log 
transformed before plotting because of skewed distribution. There is an increasing 
amount of bias with decreasing urinary albumin concentrations. The scatter plot in 
figure 2a provides a closer view on the normoalbuminuric concentration range, 
according to immunonephelometry. The mean (SD) of the urinary albumin 
concentrations as determined by immunonephelometry in the urine samples of the 
998 subjects in this range was 6.78 (4.27) mg/L versus 17.6 (10.3) mg/L for HPLC 
(P<0.001), a 159% difference. Figures 2b and 2c respectively show the scatter plots for 
the microalbuminuric and the macroalbuminuric concentration range. The mean (SD) 
of immunonephelometry was 58.9 (40.6) mg/L versus 74.0 (51.8) mg/L for HPLC 
(HPLC 26% higher, P<0.001) in the 280 subjects with immunonephelometric 
concentrations between 20-200 mg/L, and 436 (371) mg/L for immunonephelometry 
versus 399 (329) mg/L for HPLC (HPLC 8.5% lower, P=0.048) in the 34 subjects in the 
range above 200 mg/L. Following these analyses, we also investigated the agreement 
between both methods, based on 24 hour urinary albumin excretion rates. The results 
of this comparison are shown in table 2. Thirteen (2.0%) out of 662 subjects that are 
classified as normoalbuminuric by HPLC are classified as microalbuminuric by 
immunonephelometry, while 337 (34.2%) out of 986 subjects that are classified as 
normoalbuminuric by immunonephelometry are classified as microalbuminuric by 
HPLC.       
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Table 1. Population characteristics according to categories of albuminuria as detected by 
immunonephelometry. 








Male gender  % 52.3 67.8 81.4 <0.001 
Age  year 52 (12) 60 (11) 62 (10) <0.001 
Body Mass Index  kg/m2 26.4 (4.1) 28.3 (4.7) 30.8 (4.9) <0.001 
Obesity  % 17.2 30.7 41.9 <0.001 
Smoking  % 28.9 25.7 9.3 <0.001 
Waist  cm     Men 









Diabetes Mellitus  % 1.9 12.0 18.6 <0.001 
Glucose  mmol/L 4.8 (0.9) 5.5 (1.6) 6.1 (2.0) <0.001 
Anti-diabetic drugs  % 1.8 13.9 20.9 <0.001 
Systolic blood pressure  mm Hg 125 (18) 139 (20) 150 (24) <0.001 
Diastolic blood pressure  mm Hg 73 (9) 78 (9) 82 (10) <0.001 
Hypertension  % 28.0 59.9 79.1 <0.001 
Anti-hypertensive drugs  % 15.7 35.8 51.2 <0.001 
Cholesterol  mmol/L 5.4 (1.1) 5.5 (1.1) 5.4 (1.1) NS 
HDL cholesterol  mmol/L 1.04 (0.29) 0.96 (0.29) 0.95 (0.30) <0.001 
Lipid lowering drugs  % 7.8 20.0 23.3 <0.001 
Creatinine clearance  ml/min 101.2 (24.8) 100.6 (31.0) 94.6 (32.4) NS 
UAE nephelometrya  mg/24 hour 8.3 (6.1-12.9) 62.5 (40.2-107.9) 517.0 (364.5-780.6) <0.001 
UAE HPLCa  mg/24 hour 24.5 (17.8-34.1) 84.9 (56.9-134.1) 531.5 (321.6-780.6) <0.001 
ABI  %   Impaired    6.7 14.0 28.6 <0.001 
a  Data with a skewed distribution are presented as median (interquartile range). 
b P-value using ANOVA for continuous data (log transformed in case of a skewed distribution) and chi-
square for percentages. 
 
  
In the macroalbuminuric range 35 subjects were classified as macroalbuminuric by 
both methods, on 43 subjects with macroalbuminuria as classified by 
immunonephelometry and 41 subjects with macroalbuminuria as classified by HPLC.  
Table 3 shows Pearson correlation coefficients for the associations of 24 hour urinary 
albumin excretion rates as determined by immunonephelometry and HPLC with 
cardiovascular risk factors and several other variables. This analysis showed a slightly 
stronger association of urinary albumin excretion as determined by 
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Figure 1. Bland Altman plot for immunonephelometry and HPLC. The thin lines represent the zero bias 
line ± 1.96 SD limits.  
 
systolic blood pressure, diastolic blood pressure, hypertension, use of anti-hypertensive 
drugs, HDL-cholesterol, use of lipid-lowering drugs, and creatinine clearance. Urinary 
albumin excretion as determined by HPLC was somewhat more strongly associated 
with the presence of diabetes mellitus, fasting glucose concentrations, and use of anti- 
diabetic drugs. Despite the fact that the associations with cardiovascular risk factors 
were generally somewhat stronger for urinary albumin excretion rates as determined 
by immunonephelometry, we found the strongest association of urinary albumin 
excretion as determined by HPLC with the outcome parameter in our study, an 
abnormal ABI. 
Figure 3 shows the logistic regression analyses that we performed to determine 
whether HPLC predicts ABI in a similar way to immunonephelometry, either 
unadjusted or after adjustment for cardiovascular risk markers. The unadjusted odds 
ratio for macroalbuminuria as determined with HPLC (with normoalbuminuria as 
determined with HPLC as reference group) was 9.1 (95% CI 4.0-20.8, P<0.001). 
Immunonephelometry showed an odds ratio of 7.2 (95% CI 3.4-15.2, P<0.001) for 
macroalbuminuria (with normoalbuminuria as determined with immunonephelometry 
as reference group). All odds ratios decreased after adjustment for other risk factors. 
ALBUMINURIA MEASUREMENT IMMUNONEPHELOMETRY VERSUS HPLC 
 73 







0 500 1000 1500 2000


































































































































































Figure 2. Scatter plots and regression lines calculated using the least square method to determine the 
relation between immunonephelometry and HPLC, according to categories of urinary albumin 
concentrations (UAC).  
(A) Albumin concentration below 20 mg/L. (B) Albumin concentration between 20 and 200 mg/L. (C) 
Albumin concentration above 200 mg/L.  
 
 
However, the odds ratio for macroalbuminuria as determined by HPLC, 4.7 (95% CI 
1.7-12.9, P<0.05), remained higher than the odds ratio for macroalbuminuria as 




Table 2. Agreement between categories of albuminuria as determined by immunonephelometry versus 
HPLC. 








<30 mg/24hr (n=986) 649 337 0 75.2 
30-300 mg/24hr (n=283) 13 264 6 21.6 




% 50.5 46.4 3.1 100 
 
Table 3. Pearson correlations with albuminuria as determined by immunonephelometry and HPLC. 
 Immunonephelometer HPLC 
Gender -0.22* -0.22* 
Age 0.30* 0.28* 
Body Mass Index 0.28* 0.17* 
Obesity 0.21* 0.12* 
Smoking -0.05 0.00 
Waist 0.36* 0.26* 
Diabetes Mellitus 0.22 0.23* 
Glucose 0.28* 0.29* 
Anti-diabetic drugs 0.24* 0.25* 
Systolic blood pressure 0.40* 0.33* 
Diastolic blood pressure 0.36* 0.30* 
Hypertension 0.36* 0.28* 
Anti-hypertensive drugs 0.25* 0.20* 
Cholesterol 0.04 0.03 
HDL-cholesterol -0.17* -0.12* 
Lipid lowering drugs 0.17* 0.15* 
Creatinine clearance 0.07* 0.02 
Ankle-brachial index 0.13* 0.16* 
* Significance at the 0.01 level. 
 
 
For microalbuminuria the unadjusted odds ratio for HPLC was 2.5 (95% CI 1.5-4.2, 
P<0.001), and 2.4 (95% CI 1.5-3.9, P<0.001) for immunonephelometry. These values 
are 1.8 (95% CI 1.0-3.1, P<0.05) and 1.4 (95% CI 0.8-2.4, P=NS) respectively for HPLC 
and immunonephelometry after adjustment for all other risk factors: a 21% difference. 





















Figure 3. Odds ratios of a diminished ankle-brachial index according to categories of urinary albumin 
excretion determined by immunonephelometry and HPLC. * P<0.05, ** P<0.001. 
 
 
A comparison of the predictive performance of both methods using ROC curve 
analysis (figure 4), showed that there was no significant difference in the area under 
the curve (AUC) between HPLC and immunonephelometry (AUC 0.67 (95%CI 0.61-




We compared urinary albumin concentrations and 24 hour urinary albumin excretion 
rates as determined by immunonephelometry versus HPLC in a selected sub sample of 
the general population. Immunonephelometry only measures immunochemically 
reactive intact albumin whereas HPLC measures both immunochemically reactive and 
immunochemically nonreactive intact albumin.27 As might be anticipated from this 
difference between both techniques, we found higher urinary albumin concentrations 
in subjects using HPLC, compared to immunonephelometry, in the normoalbuminuric 

























































Figure 4. ROC analysis of HPLC and immunonephelometry according to a diminished ankle-brachial 
index.  HPLC is represented by the dashed line and immunonephelometry by the solid line. 
 
 
This is quite consistent with the fact that HPLC measures the same amount of 
immunochemically reactive intact albumin as immunonephelometry plus some 
amount of immunochemically nonreactive intact albumin. From the relatively low 
correlation between the two methods (r=0.61) in this urinary albumin concentration 
range, it can be seen that it is not a constant factor which is simply added on to the 
amount of immunochemically reactive intact albumin. Interestingly, in the higher 
urinary albumin concentration ranges, we did not find any indication of additional 
albumin, the regression lines almost equals the line of identity (y=x) and the mean 
value in the macroalbuminuric range was even 8.5% lower with HPLC than with 
immunonephelometry. Correlation coefficients in the higher concentration ranges 
were slightly higher for the micro- and much higher for macroalbuminuric range 
respectively. 
Our explanation for the fact that HPLC only provides higher values in samples with 
low urinary albumin concentrations is that not all immunochemically reactive intact 
albumin can be detected by currently available immunochemical methods due to as 
yet not otherwise identifiable insensitivity of the methods in the lower concentration 
ranges. Other potential explanations have been listed by Comper et al.21 In direct 
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relation to the relatively high urinary albumin concentrations detected by HPLC in the 
low urinary albumin concentration range, we found poor agreement between both 
methods in classifying subjects as normo- or microalbuminuric on the basis of 24 hour 
urinary albumin excretion rates. We confirmed the known associations of urinary 
albumin excretion with age, gender and several cardiovascular risk factors. 
Correlations of urinary albumin excretion as detected by HPLC with these known 
associates were generally weaker than with urinary albumin excretion as detected by 
immunonephelometry. When it comes to identifying subjects with prevalent peripheral 
vascular disease, indicated by a low ABI, HPLC may be a better predictor. This was 
shown by the higher odds ratios for micro- and macroalbuminuria as determined by 
HPLC. Several points concerning our study have to be addressed. Our finding of much 
higher urinary albumin concentrations using HPLC than immunonephelometry, but 
only in normoalbuminuric range (< 20 mg/L) is consistent with findings of a 
comparison between the use of HPLC and radioimmunoassay for urinary albumin 
detection in urine samples from 97 diabetic patients.21 In this latter study HPLC also 
revealed relatively high values in the low urinary albumin concentration range and 
essentially equivalent results in the higher range. It was suggested that this is specific 
for subjects with diabetes, because in 78 non-diabetic control subjects with low 
urinary albumin concentrations values revealed by HPLC were non-significantly 
(P=0.07) higher (7.5 (6.6) mg/L vs. 5.3 (4.5) mg/L) than the values revealed by RIA. 
However, our results indicate a highly significant difference in the general population. 
It seems likely the previous study was underpowered to draw conclusions about the 
absence of a difference in the non-diabetic population.21  
Future studies are necessary to elaborate on the potential superiority of urinary 
albumin determination by HPLC over immunonephelometry for determination and 
prediction of (cardio)vascular disease. It should be realized that our study has several 
limitations. First, our study is cross-sectional in nature and can, therefore, only be 
considered as hypothesis generating. Firm conclusions can only be drawn from a 
prospective cohort study. Second, it should be realized that we investigated a selected 
study population with a relatively high prevalence of micro- and macroalbuminuria. 
The prevalences of micro- and macroalbuminuria according to immunonephelometry 
in our study population were 21.6 and 3.2% resp. These are much higher prevalences 
than the 12.1 and 1.1% resp. in the original, already for microalbuminuria enriched 
cohort.23 The actual prevalence of microalbuminuria in the general Dutch population 
is estimated to be 7%.18 Thus, our study population is not representative for the 
general population.  
Another complication which decreases the generalizability of our results to the general 
population is the fact that we used data collected in subjects that have been made 
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aware of the results of the first screening of the PREVEND population. It is not unlikely 
that this has diverted the study population away from the characteristic of the general 
population. One example is the smoking prevalence in our study sample.  
During the first screening we found a smoking prevalence of 44.3% for 
normoalbuminuric subjects, 46.7% for microalbuminuric subjects, and 45.1% for 
macroalbuminuric subjects (P=NS).23 The smoking prevalence by classification 
according to immunonephelometry in our study sample is much lower, especially in 
the subjects with macroalbuminuria. One possible explanation is that awareness of 
their increased cardiovascular risk motivated relatively many subjects with 
macroalbuminuria to stop smoking between the two screenings. It should be realized 
that we used the same classic cut-off values for micro- and macroalbuminuria for both 
immunonephelometry and HPLC. This resulted in relatively few cases of 
normoalbuminuria and relatively more cases of microalbuminuria with HPLC as 
compared to immunonephelometry, because HPLC provides higher values especially 
in the low range of concentrations. The number of macroalbuminuric subjects was 
roughly the same with both methods. Thus, using the 30 mg/24 hour cut-off point, 
more patients were identified as having microalbuminuria with HPLC than with 
immunonephelometry. Notwithstanding, those patients identified by HPLC had a 
similar absolute risk for prevalent peripheral vascular disease (diminished ABI) when 
compared to those identified with immunonephelometry (29 out of 283 patients 
versus 53 out of 609 patients, respectively, P=NS). When confirmed in prospective 
studies, these findings may have consequences for population screening since 




We have shown that detection of total intact urinary albumin by HPLC provides 
different values than immunonephelometry, which only measures immunochemically 
reactive intact albumin. The difference between the two methods is especially present 
in the normoalbuminuric concentration range. Urinary albumin excretion as 
determined by immunonephelometry is generally somewhat more strongly correlated 
to cardiovascular risk factors, but HPLC was more strongly related to prevalent 
peripheral vascular disease, with a 21% higher independent odds ratio for 
microalbuminuria, and a 30% higher independent odds ratio for macroalbuminuria. 
However, future research is needed because our study was cross-sectional in a 
selected population.  
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Urinary albumin excretion (UAE) is a predictor of mortality. Urinary albumin is 
conventionally measured using immunochemical methods. An HPLC method has been 
suggested to measure immunochemically nonreactive albumin in addition to 
immunochemically reactive albumin. We investigated whether albumin assessed by 
HPLC adds to immunonephelometry in the prediction of cardiovascular and total 
mortality.     
A sample (n=3485) of the general population was followed from ’97-’98 until 
December 2004 (PREVEND study). Vital status was evaluated through the municipal 
register and cause of death obtained from the Dutch Central Bureau of Statistics. Cox-
regression analyses were performed to investigate whether UAE assessed by HPLC 
adds to UAE assessed by immunonephelometry in predicting mortality.  
Median (IQ range) UAE measured by HPLC was higher than by immunonephelometry 
(22.9 (11.7-36.3) versus 4.7 (3.5-7.0) mg/24 hour, P<0.001). During a median follow-
up of 2388 days, 340 subjects died (100 from cardiovascular causes). Univariately, 
hazard ratios (95% confidence intervals) for predicting cardiovascular and total 
mortality were 5.2 (4.1;6.6) and 4.2 (3.6;4.8) by immunonephelometry and 7.6 
(5.1;11.4) and 6.0 (4.8;7.5) by HPLC (all P<0.001). Areas under the curve in ROC 
analyses were non-significantly lower for HPLC than for immunonephelometry (P=0.09 
for cardiovascular mortality and P=0.24 for total mortality). Multivariate analyses 
revealed interaction between immunonephelometry and HPLC-assessed UAE for both 
end-points (P<0.01), with both assays additive to each other in predicting in the lower 
range of UAE.    
HPLC detects more albumin than immunonephelometry, particularly in the lower 
ranges according to immunonephelometry. The “extra” albumin identified by HPLC 
improves the prediction of cardiovascular and total mortality by albumin measured by 
a standard immunochemical assay. 
 





Albuminuria is an independent predictor of cardiovascular and total mortality in the 
general population.1 Urinary albumin is traditionally measured using immunochemical 
methods such as radio-immuno-assay and immunonephelometry. It was recently 
suggested that urine not only contains immunochemically reactive albumin detected 
by immunochemical assays, but also immunochemically nonreactive albumin, 
detectable by a size-exclusion based high-performance liquid chromatography (HPLC) 
method.2-4 This new HPLC assay measures higher albumin concentrations, with largest 
differences in the normoalbuminuric and microalbuminuric range.5-7  
The meaning of this additive albuminuria is under debate. Some investigators have 
doubts about the validity of the HPLC technique as far as measuring only albumin.8,9 
These authors suggest that the difference is made at least in part by additional 
detection of up to 30% of other proteins. The question, however, remains whether the 
extra detected proteins, including so-called immunochemically nonreactive albumin, 
have any diagnostic and or pathophysiological relevance.  
In the microalbuminuric range, HPLC measures ~3 times higher than 
immunonephelometry.5 This results in higher prevalence of microalbuminuria,5-7 and 
earlier detection of diabetic nephropathy.9 In all these studies, including the latter 
prospective study on diabetic nephropathy, the same cut-off value was used for 
defining nephropathy by both assays. Because albumin levels are higher with HPLC, 
the earlier detection may just have been the consequence of this use of the same cut-
off values for both assays. Such a potential self-fulfilling prophecy in earlier prediction 
can be circumvented by comparing both assays as predictor of an endpoint which is 
not dependent on a definition based on urinary albumin. 
We investigated whether assessment of urinary albumin by HPLC adds to the 
prediction of (cardiovascular) mortality by urinary albumin assessed by 
immunonephelometry. This study was carried out in a random sample of the general 
population, which had been followed for mortality for 7 years. Baseline albumin levels 
were measured in frozen urine samples. Since freezing is likely to have an effect on 
the assessed albumin concentration,10 we additionally determined the effect of frozen 
storage on albumin concentration measured by HPLC and immunonephelometry in a 





We performed our study in the framework of the PREVEND (Prevention of Renal and 





This prospective cohort study was designed to investigate urinary albumin excretion as 
predictor for cardiovascular and renal disease. Study details are described elsewhere.11 
After the baseline screening in 1997, participating subjects visit our outpatient clinic 
once every three years for follow-up measurements. At entry into the study, all 
participants were asked to collect 24 hour urine samples in plastic containers, and to 
store the urine at 4°C up to a maximum of 2 days prior to the visit in the out-patient 
clinic. Aliquots of these 24 hour urine collections were then stored frozen at -20°C.  
 
STUDY POPULATION 
The PREVEND study population (n=8592) is enriched for microalbuminuria. To study 
the predictive properties of albuminuria, the enriched part of the PREVEND study 
(UAC>10 mg/L) was reweighed by proportionally taking a SPSS generated random 
subset (n=3432). Subjects were excluded if leucocyturia and/or erytrocyturia was 
present (leukocytes >75/μL, or erythrocytes >50/μL, or leukocytes =75 and 
erythrocytes >5 μL measured by dipstick in the 24 hour urines). Subjects were also 
excluded when known with proteinuria or renal disease. This resulted in a random 
subset of 3249 subjects. In this random subset, 104 subjects died, during follow-up 
from 1997-1998 until December 2004. Power calculations indicated that to detect a 
relevant difference in predictive power between albuminuria assessed by 
immunonephelometry and HPLC, 330 cases would provide a power of 90% with α at 
0.05. In the total PREVEND cohort 340 subjects died, providing a power of 91%. The 
dataset was therefore enriched for the additional subjects that died (n=340-104=236), 
resulting in a final study population of 3485 subjects. From the time of recruitment, the 
vital status of all participants was evaluated trough the municipal register. If 
participants died, cause of death was obtained by linking the number of the death 
certificate to the primary cause of death as coded by the Dutch Central Bureau of 
Statistics. Survival time for the participants was defined as the period from the date of 
the first screening in the outpatient clinic until the date of death or the 31st of 
December 2004. If a person had moved to an unknown destination, the person was 
censored on the last available date. 
 
DEFINITIONS AND LABORATORY MEASURES 
Body mass index (BMI) was calculated as the ratio of weight and height squared 
(kg/m2). Blood pressure was measured every minute during ten minutes at the first visit 
and every minute during eight minutes at the second visit. Blood pressure data were 
calculated from the average of the last four blood pressure values of each visit. 
Smoking was defined as current smoking. Type 2 diabetes was defined as a fasting 
glucose of >7.0 mmol/L or a non-fasting glucose level of >11.1 mmol/L or use of anti-




diabetic drugs. Serum creatinine, serum cholesterol, and plasma glucose were 
determined by Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, NY, USA). 
A commercially available assay system was used to access HDL (high density 
lipoprotein) (Abbott Inc, Abbott Park, Illinois, USA). Triglycerides were measured 
enzymatically. High sensitive C-reactive protein was determined by 
immunonephelometry (threshold 0.175 mg/L and intra- and interassay coefficient of 
variation of 4.4 and 5.7%, respectively).  
 
MEASUREMENT OF URINARY ALBUMIN CONCENTRATION 
Urinary immunochemically reactive albumin was measured by immunonephelometry 
(Dade Behring Diagnostics, Marburg, Germany) with a threshold of 2.4 mg/L. The 
intra-assay coefficients of variation (CV) and between-day CV were 2.7% and 4.5%, 
respectively. HPLC assessments were performed using a Waters Alliance HPLC, based 
on size-exclusion with a threshold of 1.0 mg/L. The intra-assay CV and between-day 
CV were 2.6 and 5.6% respectively. Aliquots of urine (25 μL) were injected onto a 
Zorbax Bio series preparative GF 250 column (9.4 mm ID x 25 mm). The mobile 
phase was phosphate-buffered saline (9 g/L NaCl, 0.775 g/L Na2HPO4, 0.165 g/L 
KH2PO4, pH 7.4) run at a flow of 0.5 mL/min.  
A subset of urine samples (n=295) from consecutive participants in the third screening 
of the PREVEND study (2004/2005) was used to compare the effect of frozen 12 
months of frozen storage at -20°C between both assays. Samples with a fresh 
concentration of immunochemically reactive albumin <5 mg/L were not stored to 
ensure potential detection of decline with storage, given the lower limit of detection of 
the assay of 2.4 mg/L. For fresh determination of albuminuria by 
immunonephelometry and HPLC, samples were kept at 4°C in polystyrene tubes for a 
maximum of 3 days. Both fresh and frozen samples after thawing were subjected to 
hand-inversions and centrifuging prior to assessment, and then immediately analyzed. 
  
STATISTICAL ANALYSES 
Comparisons of baseline characteristics for survivors versus non-survivors were 
performed by t-tests for continuous variables, by Mann-Whitney tests for variables with 
skewed distribution and by Chi-square test for categorical variables. 
For analyses of albuminuria as predictor of cardiovascular and total mortality, albumin 
excretion rates were log10-transformed. We first performed univariate Cox 
proportional hazard analyses of albuminuria by immunonephelometry and HPLC as 
predictors of mortality. In these analyses, the hazard ratio (HR) per unit change in 
log10-transformed urinary albumin excretion (log10NEPH for immunonephelometry 





immunonephelometry and HPLC respectively. Because magnitudes of HRs depend on 
the range of assessed concentrations in the population rather than on the strength of 
the association per sé, we used receiver operating characteristic (ROC) curves to 
actually compare the predictive properties of albuminuria assessed by nephelometry 
and HPLC with each other. It is, however, inappropriate to use ROC curves to 
investigate whether two variables are additive in predicting events.12 Multivariate Cox 
regression analyses are more appropriate for this purpose. We performed multivariate 
analyses in which both methods were included, and potential interaction was tested 
for statistical significance by inclusion of a product-term of both assays. The hazard 
ratio for each value of log10NEPH and log10HPLC in such an analysis can be 
calculated from e(β1×log10NEPH + β2×log10HPLC + β3*log10NEPH*log10HPLC). A P-value of <0.05 was 
considered significant. A P-value of <0.10 was considered significant for interaction 




Baseline characteristics of the study population are shown in table 1. Mean age (SD) 
at baseline was 50 (13) years. The studied sample contained 48% men. During a 
median follow-up of 2388 days (maximum 2649 days) 340 subjects died, of which 100 
from cardiovascular causes. Compared to subjects who survived, non-survivors were 
generally older, more frequently male and more frequently smoker. Blood pressure, 
serum creatinine, and fasting glucose were higher in the non-survivors, as was the 
prevalence of diabetes mellitus. 
The median (interquartile range) urinary albumin excretion (UAE) was 4.7 (3.5-7.0) 
mg/24 hour when assessed by immunonephelometry and 22.9 (11.7-36.3) mg/24 
hour by HPLC (P<0.001). Discrepancies between both methods in the normo-, micro- 
and macroalbuminuric range according to urinary albumin assessed by 
immunonephelometry are shown in figure 1. It appears that differences between both 
methods are particularly present in the normo- and microalbuminuric range. In the 
normoalbuminuric range there are for instance subjects in whom UAE is 3 mg/24 hour 
according to immunonephelometry, and 53 mg/24 hour according to HPLC, which 
represents an absolute difference of 50 mg/24 hour.  
 
We proceeded with univariate Cox-regression analyses of UAE assessed by 
immunonephelometry and HPLC as predictors of cardiovascular and total mortality. 
Urinary albumin excretion determined by immunonephelometry predicted both 
cardiovascular (HR (95% CI)=5.2 (4.1;6.6), P<0.001) and total mortality (HR (95% 
CI)=4.2 (3.6;4.8), P<0.001).     




Table 1. Population characteristics, overall, and according to survival status. 




Subjects, N 3485 3145 100 340 
Age, year 50 (13) 48 (12) 66 (8)** 63 (10)** 
Male gender, % 48 46 74** 68** 
Body mass index, kg/m2 25 (4) 26 (4) 28 (4) 27 (4) 
Smoking, % 32 31 37** 41** 
SBP, mm Hg 127 (19) 126 (18) 150 (24)** 142 (24)** 
DBP, mm Hg 73 (9) 73 (9) 81 (9)* 78 (10)* 
Cholesterol, mmol/L 5.6 (1.1) 5.6 (1.1) 5.8 (1.1) 5.9 (1.1) 
HDL, mmol/L 1.4 (0.4) 1.4 (0.4) 1.2 (0.4) 1.3 (0.4) 
Triglycerides, mmol/L 1.4 (0.9) 1.4 (1.0) 1.5 (0.7) 1.5 (0.8) 
Glucose, mmol/L 4.8 (1.0) 4.7 (1.0) 5.3 (1.2)** 5.3 (1.3)** 
Diabetes, % 1.5 1.0 5.1** 6.2** 
UAE NP, mg/24 hour 4.7 (3.5-7.0) 4.6 (3.5-6.3) 14.4 (5.8-53.0)** 9.1 (4.9-33.5)** 
UAE HPLC, mg/24 hour 22.9 (11.7-36.3) 21.7 (10.9-34.1) 44.9 (26.2-95.7)** 39.3 (23.4-80.9)** 
* P<0.05 for subjects who died versus survivors. 
** P<0.001 for subjects who died versus survivors. 
 
This indicates that subjects with a UAE of 30 mg/24 hour have a 4.2 fold higher 
chance of dying than subjects with a UAE of 3 mg/24 hour, and a 4.2 fold lower 
chance than subjects with a UAE of 300 mg/24 hour. For HPLC, the corresponding 
values were 7.6 (6.0-11.4) and 5.9 (4.8;7.5), both with P<0.001. We used ROC curve 
analyses to compare the predictive properties of albuminuria assessed by 
immunonephelometry and HPLC. Areas under the curve (95% CI) for prediction of 
cardiovascular mortality by immunonephelometry and HPLC were 0.74 (0.73-0.75) 
and 0.70 (0.69;0.72) respectively (P=0.09 for comparison of both areas). To study the 
additive effect of both assays on each other multivariate Cox-regression analyses were 
performed. Corresponding values for prediction of total mortality were 0.74 (0.72-
0.75) and 0.72 (0.70;0.74) (figure 2, P=0.24 for comparison of both areas). This 
revealed significant additive interaction for immunonephelometry and HPLC, both in 
predicting cardiovascular mortality (P<0.01) and total mortality (P<0.001). Figure 3 
shows a graphical interpretation of this interaction for total mortality. Results for cases 
in which HPLC analyses result in 10, 20, 30, 40 and 50 mg/24 hour higher excretions 
of urinary albumin than immunonephelometry are presented. Subjects with a UAE of 3 
mg/24 hour by both immunonephelometry and HPLC were considered as reference, 





     
    
























Figure 1. Relation between immunonephelometry and HPLC, according to the clinical categories of 
urinary albumin excretion (UAE) as assessed by immunonephelometry. A. Excretion below 30 mg/24 
hour. B. Excretion between 30-300 mg/24 hour. C. Excretion above 300 mg/24 hour.    
 
 
Subjects with a UAE of 3 mg/24 hour by immunonephelometry and 33 mg/24 hour 
by HPLC have a HR of 2.8, while subjects with a UAE of 10 mg/24 hour by 
immunonephelometry and a UAE of 40 mg/24 hour by HPLC have a HR of 5.6 (these 









































































































































































Figure 2. ROC analysis of HPLC and immunonephelometry according to total mortality. HPLC is 
represented by the dashed line, immunonephelometry by the solid line. 
  
 
For our studies on prediction of cardiovascular and total mortality, we used urine 
samples that had been stored frozen at -20°C for an average (SD) of 7 (0.4) years 
before assessment of urinary albumin by immunonephelometry and HPLC. 
We performed a sub study to investigate whether there is a differential effect of frozen 
storage at -20°C on urinary albumin assessed by immunonephelometry and HPLC. The 
median fresh urinary albumin concentration assessed by immunonephelometry was 
significantly lower than by HPLC (11 (7-51) versus 55 (34-111) mg/L, P<0.001). The 
median change in albumin concentration after frozen storage was -32.1 (-61.5;-10.4)% 
for immunonephelometry and -53.4 (-70.8;-4.1)% for HPLC (P<0.001). In figure 4 it can 
be seen that in the normoalbuminuric range (urinary albumin concentration <20 mg/L 
according to immunonephelometry) there are many fresh samples in which HPLC 
assessed urinary albumin is higher than 50 mg/L (figure 4a), whereas this is sporadic 
after frozen storage for 12 months (figure 4b). The same phenomenon is visible to a 
lesser extent in samples with immunonephelometric concentrations between 20 and 
200 mg/L (figure 4c versus 4d).  
 















































Figure 3. Graphical interpretation of the additive prediction of total mortality by albuminuria measured 
by immunonephelometry and HPLC. Multivariate Cox-regression analyses revealed significant interaction 
between immunonephelometry and HPLC with β (95% CI) 1.78 (1.28-2.29), P<0.001 for 
immunonephelometry, 1.17 (0.74-1.60), P<0.001 for HPLC, and -0.38 (-0.61;-0.15), P<0.01 for the product-
term of both assays. The HRs for each value of log10NEPH and log10HPLC can consequently be calculated 
from e1.784*log10NEPH+1.171*log10HPLC-0.383*log10NEPH*log10HPLC. Grey dots indicate examples of HRs for 3 mg/24 hour by 




This is the first prospective study to demonstrate that additional assessment of urinary 
albumin by HPLC adds to the prediction of cardiovascular and total mortality by 
albuminuria assessed by immunonephelometry. Subjects with urinary albumin 
excretion rates in the normoalbuminuric range (<30 mg/24 hour) according to 
immunonephelometry, which are generally assumed to be at low risk, have a much 
higher risk if there is a considerable mismatch between both assays.  































































































Figure 4. Effect of frozen storage at -20°C for 12 months on the relation between immunonephelometry 
and HPLC, according to the normo- and microalbuminuric range respectively. Immunonephelometry is 
indicated by NP. 
 
 
With increasing urinary albumin excretion rates according to immunonephelometry, 
the already high risk is increasingly less modified by mismatches between both assays. 
Our study shows that it is worthwhile for risk assessment to additionally perform an 
HPLC assay in subjects with low urinary albumin excretion according to 
immunonephelometry, but not in subjects with high urinary albumin excretion 
according to immunonephelometry (and vice versa).  
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To date, there are, only two other prospective studies that investigated HPLC-assessed 
urinary albumin as a predictor of events. One was on prediction of diabetic 
nephropathy, and concluded that HPLC assessment of urinary albumin results in 
earlier detection of microalbuminuria than classic immunochemical detection.9 
Because the definition of microalbuminuria depends on cut-off values, and the same 
cut-off was applied for both assays, it can not be excluded that the same result could 
have been obtained with lowering of the cut-off value defining microalbuminuria for 
the immunochemical assay. The other prospective study investigated the significance 
of albumin assessed by HPLC in comparison to RIA as predictor of cardiovascular 
events (MI, stroke, and CV death) in the HOPE study (n=5358, including 1992 patients 
with diabetes mellitus) with follow-up for 4.5 (range 3.5-5.5) years.7 The authors 
concluded that HPLC- and RIA-measured urinary albumin have similar predictive 
properties. Unlike our study, it was not investigated whether it could be of value to 
perform HPLC-assays in addition to RIA-assays in the same urine sample.  
The HPLC assay was not yet available at time of baseline measurements for our study. 
We therefore used samples which were stored frozen 7 years ago. In previous studies, 
we showed that for immunonephelometry, long-term frozen storage at -20°C results in 
a significant decrease in assessed albumin concentrations, in particular in the lower 
range of concentrations, and a significant decrease in predictive power of urinary 
albumin for mortality.10,13 All studies on HPLC-assessed albumin used urine samples 
that had been stored frozen before performance of HPLC measurements. Some 
studies compared these HPLC results from frozen samples to immunochemical assays 
in fresh samples,5-7,14,15 whereas others used frozen samples for both assays.3,9,16 Since 
we knew that frozen storage affects urinary albumin concentrations,13 we chose to 
perform both assays from frozen samples for this study, and analyse the samples 
simultaneously. Concerning assessment of urinary albumin by HPLC there are no data 
available on long-term storage. Osicka and Comper did not find a significant change in 
amount of albumin detected by HPLC with freezing for up to 2 months at both -20°C 
and -80°C.3 The power of this study for finding significant changes can, however, not 
be judged from this report. We therefore performed an additional study in which we 
found HPLC to be more susceptible to loss in albumin concentration than 
immunonephelometry. It must be concluded that other studies that used frozen urine 
samples and applied cut-off values erroneously drew conclusions on prevalences of 
subjects with normo-, micro-, and macroalbuminuria.6,7 Although we analysed the 
albumin data on a continuous scale and did not use cut-off values, the freeze-effect 
may have caused that the additive predictive effect of measurement by HPLC was 
underestimated. Studies need to be performed in which both albumin measured by 
immunonephelometry and HPLC are assessed in fresh urine samples.  




We can only speculate why urinary albumin assessed by HPLC is more susceptible to 
frozen storage than immunonephelometry. The albumin that is immunochemically 
nonreactive to currently available antibodies is a form of native albumin subjected to 
proteolytic cleavage, but maintained at an intact relative mass by disulfide bonds.4 For 
immunochemical assays, it is usually thought that decline in detectable albumin 
concentrations is the consequence of aggregation or degradation. It may well be that 
this immunochemically nonreactive albumin is more likely to form aggregates or to 
degrade into smaller pieces than immunochemically reactive albumin. It is thought that 
lysosomal degradation is in one way or another involved in the origin of the 
appearance of immunochemically nonreactive albumin in urine.4,17 Interestingly, this 
form of albumin is especially present at low concentrations of urinary albumin. One 
explanation may be that appearance of immunochemically nonreactive albumin in 
urine is an early phenomenon in the course of development of albuminuria, and that 
the more advanced the protein leakage becomes, the more overloaded the lysosomal 
machinery is with other proteins, with disappearance of albumin modified by 
lysosomes from urine.  
Recently, the accuracy of the measurement of urinary albumin concentration by the 
HPLC method has been questioned.8 By using mass-spectrometry, Sviridov et al. found 
that the albumin peak assessed by HPLC was not exclusively albumin but contained 
also approximately 20% other proteins such as transferrin and α1-acid glycoprotein, a 
result which is highly contrasting with the results of an earlier study.3 The differences 
between both studies, however, make them difficult to compare and to be conclusive 
on this subject. Further studies will be needed to investigate the content of the HPLC 
peak and to determine whether a potential excess of other proteins excreted by the 
kidneys will have clinical implications. 
Our study (and all other studies on HPLC-assessed urinary albumin) is limited by the 
fact that we used frozen urine samples. However, the results of our study are of 
importance because the HPLC-assay may therefore be even stronger in additive 
prediction of events in subjects with low UAE according to immunonephelometry and 
other immunochemical albumin assays when using fresh urine samples. 
In conclusion, when either immunonephelometry or HPLC is used to assess urinary 
albumin, predictive properties are similar, but when both measurements are combined 
in the same urine sample, assessment of albuminuria by HPLC in addition to 
immunonephelometry adds to the predictive value for cardiovascular and total 
mortality. Albuminuria assessed by HPLC might therefore be valuable for risk 
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The history of the term microalbuminuria dates back to 1981, when it was shown that 
concentrations of urinary albumin that can not be detected by standard dipsticks, 
predict development of overt proteinuria in patients with diabetes.1,2 A few years later, 
in 1984, it was shown that low levels of albuminuria also predict mortality in patients 
with diabetes.3,4 Although the clinical application of microalbuminuria is still largely 
limited to the area of diabetes, it soon became clear that the predictive properties of 
microalbuminuria go beyond diabetes: at the end of the eighties it was demonstrated 
that microalbuminuria is predictive of mortality and vascular disease in non-diabetic 
subjects of the general population.5,6 During the last decade, it has become evident 
that  microalbuminuria is an independent predictor of total and cardiovascular 
mortality, and also of cardiovascular morbidity in patients with diabetes, hypertension, 
and in the general population.7-16 
 
SCREENING FOR AND MONITORING OF MICROALBUMINURIA 
Is it then worthwhile to screen and/or monitor for microalbuminuria? It certainly is in 
patients with diabetes. Early detection and treatment with blood pressure lowering 
drugs, especially drugs that intervene in the renin-angiotensin-aldosteron system 
(RAAS) - has been shown to at least delay, and possibly even prevent, development of 
end-stage renal disease in patients with diabetes mellitus and 
macroalbuminuria/proteinuria.17,18 In a post-hoc analysis of one of these trials, the 
RENAAL study, it was shown that the reduction in albuminuria achieved after six 
months of treatment, strongly predicted the long-term renal function outcome.19 
Besides the reduction in albuminuria, residual albuminuria during treatment was 
strongly associated with the rate of decline in renal function.19 In another trial, it was 
found that roughly the same findings applied to the reduction of proteinuria.20  
The reduction in albuminuria achieved by treatment also appears to be important from 
a cardiovascular perspective. Another post-hoc analysis of the RENAAL study showed 
that every 50% reduction in albuminuria is associated with an 18% reduction in 
cardiovascular risk and a 27% reduction in the risk for heart failure.21 Recent studies 
suggest that the renoprotective effect of such treatment in patients with diabetes also 
extends into the microalbuminuric,22 and even into the normoalbuminuric range.23 
Interestingly, it has been reported that the rates of end-stage renal disease due to type 
1 diabetes in the Netherlands have been declining in recent years, although the 
incidence of DM 1 doubled every 20 years.24 The same has been observed in the 
USA.25 It is likely that this has to be attributed to an increasing habit of early 
intervention with renoprotective intervention in patients with diabetes. Little is known 
whether early detection of microalbuminuria might also actually benefit non-diabetic 
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subjects in the general population. Population screening may be feasible from the 
perspective of early prevention of the upcoming epidemic of end-stage renal disease, 
due to Western life style and longevity.26,27 The same may be true from a 
cardiovascular point of view.27  
An advantage of detection of albuminuria over screening for other risk factors is that it 
only requires a portion of urine, which could be sent in by post, rather than a costly 
visit to a physician or health center, with or without venipuncture. In this sense, it is 
not a prerequisite that microalbuminuria is an independent risk factor, because it could 
be economically advantageous to use it as only a screening factor for identification of 
subjects at risk. Such an approach was tested for cost-effectiveness by Atthobari et al. 
using data from the Prevention of Renal and Vascular End-Stage Disease Intervention 
Trial (PREVEND IT).28 They calculated that from the Dutch health care perspective, 
screening of the general population for albuminuria, and subsequent treatment with an 
ACE inhibitor in case subjects that are found to be microalbuminuria positive, is cost-
effective compared to no screening. These encouraging data require, however, 
confirmation from larger multicentre trials and other populations.    
 
HOW TO SCREEN FOR MICROALBUMINURIA? 
Since albumin excretion follows a circadian rhythm, assessment of albumin excretion 
in a 24 hour urine collection is considered the ‘gold standard’ for detection of 
microalbuminuria.29 However, this procedure is cumbersome and may be inaccurate 
due to collection errors. There is an ongoing debate whether either albumin 
concentration or the albumin to creatinine ratio (ACR) from a spot morning void can 
be used as alternatives, and which one is best.30-32 Both of these alternatives have their 
advantages and disadvantages. The albumin concentration is sensitive to urinary 
volume, and its use without correction for dilution may be associated with a lower 
specificity and sensitivity for detection and prediction of disease than 24 hour urinary 
albumin excretion. The ACR, in which the albumin concentration is divided by the 
urinary creatinine concentration, thus correcting for variations in urinary volume, goes 
together with an extra measurement and hence additional variation and costs. Of 
note, urinary creatinine excretion is not only determined by the degree of 
concentration, but also by muscle mass, and consequently by gender, age, and race. It 
has therefore been advocated that for the ACR gender specific cut-off values defining 
microalbuminuria should be used, and perhaps even age-dependent cut-off values.33,34 
Introducing different cut-off values for various subgroups limits of course the practical 
use of the ACR. Many studies, some of them recently published, have evaluated the 
performance of the urinary albumin concentration, ACR and use of semi quantitative 
albumin test strips in comparison to 24 hour albuminuria.30-32 However, most studies 
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included a relatively small number of patients, used different reference procedures (24 
hour versus timed overnight sampling), variable cut-off values for the reference 
procedure, and used different types of urine collections (first morning void versus 
random urine void), as reviewed by Bakker.35 This complicates direct comparison 
between studies. In the largest study hitherto, Gansevoort et al. evaluated the 
performance of the albumin concentration and ACR in predicting microalbuminuria in 
subsequent 24 hour urine collections.36 For this study, 2527 subjects collected a first 
morning urine void in which the albumin concentration and ACR was determined. It 
was then analyzed whether either the urinary albumin concentration or the ACR was 
more strongly predictive of the presence of microalbuminuria in a ‘gold standard’ 24 
hour urine collection gathered a few weeks later. After analyzing the data, using 
Receiver-Operating-Characteristics (ROC) curves, it appeared that there was hardly 
any difference between the urinary albumin concentration and ACR in the ability to 
predict the presence of microalbuminuria. The area under both ROC curves was 
satisfactory and moreover similar (0.92 versus 0.93, P=NS). These data suggest that 
screening based on determination of UAC or ACR in a spot urine sample is feasible. It 
should be noted that in this study the presently used cut-off values defining 
microalbuminuria for albumin concentration and for ACR resulted in a substantial 
number of false negative results with respect to predicting the presence of 
microalbuminuria in the subsequent 24 hour urine collections. One might argue that 
for screening purposes lower cut-off values should be used, and it was suggested that 
the optimal value for the albumin concentration is just above 10 mg/L.36 This notion 
needs, however, confirmation. There are other issues that have to be resolved before it 
can be decided whether assessment of albumin concentration or the ACR in a spot 
urine can replace the ‘gold standard’ 24 hour albuminuria. It is important to investigate 
which of the albuminuria measures shows the least intra-patient coefficient of variation 
(CV). Dyer et al. studied the intra-individual CV of the urinary albumin concentration, 
the albumin excretion and albumin:creatinine ratio and found this to be 30-80%.37 In 
chapter 6 we respond to this study by calculating these albumin measures in the 
PREVEND IT trial. We found much smaller CV’s, and this difference between the two 
studies probably originates from the fact that Dyer et al. used frozen urine samples to 
assess the albumin concentration while in the PREVEND IT study fresh samples were 
used. Interestingly, we found that the within-person CV is time-dependent: when the 
time between collections is longer, the CV is larger. These differences, however, make 
it difficult to compare studies investigating this topic. We furthermore note that for the 
assessment of the albumin concentration, excretion, and ACR the 24 hour collection 
was used while in the clinical practice spot morning urine samples are used. Besides 
the difference in within-person CV of the albuminuria measures, another important 
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aspect in this discussion is which albuminuria measure performs best in its ability to 
predict cardiovascular and renal outcome.  
  
STORAGE OF URINE PRIOR TO ASSESSMENT 
It is common that large epidemiological studies and clinical trials freeze biological 
samples prior to assessment, both for reasons of convenience and to allow for 
performance of assessments in an as short as possible period of time, to keep assay 
variation as low as possible. It is questionable whether freezing is also optimal in the 
case of urinary albumin assessment. Few studies have investigated the effect of 
prolonged frozen storage, and until recently these studies were small, with samples in 
the macroalbuminuric range. Chapter 2 describes our study on this topic which is the 
largest (n = 1785) and longest (up to two years of frozen storage at -20°C) to date in 
this field, with the majority of samples in the normo and microalbuminuric range. In 
this study we not only found that sample handling by vortexing or hand inversions is of 
great importance for an optimal result, but also that a certain degree of decline is 
inevitable, in particular in the normo and microalbuminuric range. A decline in the 
macroalbuminuric range was also present, but it was significantly lower than in the 
other samples. A fixed decline would not be a problem for studies on changes in 
response to treatment or time. It appeared, however, that there was great variation 
between samples from the effect of freezing. In chapter 3 we showed that prolonged 
frozen storage of 7 years indeed leads to an increase in variability. Our study 
contained 3432 subjects of which two urine samples on two consecutive days were 
present. This unique property of the study made it possible to calculate the biological 
and total coefficient of variation (CV). Using the formula CV2total = CV
2
analytical+biological + 
CV2freezing we calculated that the between day CV for fresh samples was 24, 26, 25, 
and 16% for the <10, 10-20, 20-200 and >200 mg/L categories respectively, and 27, 
40, 37, and 23% after freezing. We therefore found that freezing introduced an 
additional CV of 12, 30, 27, and 17% in the respective categories. We furthermore 
showed in this chapter that freezing results in a decrease in predictive performance of 
albuminuria for mortality. This effect of freezing is a serious thread to the interpretation 
of longitudinal studies that investigate the value of albuminuria in predicting clinical 
outcome, but use urine samples that have been stored frozen for prolonged periods of 
time.    
It has been suggested that frozen storage at -70°C or -80°C is superior to frozen 
storage at -20°C in preventing decreases.38,39 There are only few studies that have 
further investigated this issue. Schultz et al. studied differences in albumin 
concentrations after 8 months of storage at -70°C compared to -20°C, but they did not 
perform fresh assessments, so they could not investigate whether storage at -70°C 
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actually prevented losses during storage.40 Another previously performed study, in 
which 12 urine samples with a median initial albumin concentration of 7 mg/L, were 
stored at -20°C and -80°C for up to 6 months, found only a trend, but no significant 
difference between both storage temperatures.38  
The studies described in chapters 2 and 3 of this thesis were not designed to 
investigate the cause of the decreases after storage. Several explanations have been 
proposed but never thoroughly studied. To shed some light on possible mechanisms 
of decrease, we investigated a potential relationship between the initial pH of urine 
and a decline after storage (chapter 4). The isoelectric point of albumin is 4.7 and 
urine at low pH may therefore cause increased aggregation and denaturation of 
albumin. Indeed, we found that urinary pH is associated with the magnitude of decline 
in urinary albumin assessed after frozen storage for one year. Other explanations 
concerning the decline in albumin concentration after storage might be the 
entrapment of albumin in the precipitate, bacterial contamination, conformational 
changes, and the attachment of albumin molecules on the tube wall. Further studies 
concerning this aspect of sample conservation have to be performed.  
In chapter 5 we studied whether the decreases in albumin concentration after frozen 
storage could be prevented by storage at lower temperatures. We subsequently found 
that storage for one year at -80°C indeed prevents a change in albumin when assessed 
by immunonephelometry.   
                   
A NEW ASSAY FOR ASSESSMENT OF URINARY ALBUMIN 
Urinary albumin is complex and exists in multiple forms. Currently, there is no 
consensus how to measure urinary albumin. Traditional assays are based on 
immunochemical methods such as immunoelectrophoresis, immunonephelometry, 
radioimmunoassay, and immunoturbidimetry, and may use antibodies raised against 
serum albumin rather than urinary albumin. These traditional assays detect 
immunochemically reactive albumin and other compounds with albumin-
immunoreactivity, including polymer albumin aggregates and albumin fragments 
>12kDa.41-43 Recently, a new method, using high performance liquid chromatography 
(HPLC) has been developed, that determines urinary albumin based on its size. Studies 
in animals and humans using this size exclusion HPLC method have shown that urine 
contains both an immunochemically reactive portion of albumin and an additional 
portion of ‘immunochemically unreactive’ albumin, which is not detected with 
conventional immunoassays.44,45 It has been hypothesized that the immunochemically 
unreactive albumin is an intact, although damaged, protein with cleaved peptide 
chains. This cleavage would be the consequence of exposure to lysosomal enzymes. 
In this scenario, the whole molecule remains together by noncovalent disulfide bonds. 
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Due to the loss of peptide chains, the albumin molecule is not recognized by 
immunochemical techniques, but can be detected by means of HPLC.46 
When urine samples are measured using the HPLC assay a substantial percentage of 
patients initially characterized as normoalbuminuric should be reclassified as 
microalbuminuric. A study with 97 patients with diabetes reported that 33% of 
subjects were classified as normoalbuminuria by immunochemical assays but were in 
the microalbuminuric range when measured with HPLC.45 In chapter 7 we showed 
that in the PREVEND cohort study, with high prevalence of microalbuminuria, it was 
necessary to re-classify 34.2% of the subjects that were initially classified as 
normoalbuminuric to microalbuminuric according to HPLC. Furthermore, the relation 
between albuminuria assessed by the two methods and peripheral vascular disease 
was studied. By using ROC analysis, no significant difference was found but when 
applying the classic cut-off values we found HPLC assessed albumin to show a 
stronger relation with PVD than albuminuria by immunonephelometry. Similar results 
were found in an Australian cohort of 10,010 subjects, representing the general 
population. According to HPLC assessment, 17.4% of the total cohort changed from 
normo to microalbuminuria. This change in albuminuria category was furthermore 
associated with an increased odds ratio for CVD in women, patients with treated and 
untreated hypertension, and patients with impaired fasting glucose or diabetes. 47 A 
recent study performed within the HOPE-study showed that the prevalence of 
microalbuminuria with HPLC assessed albumin is 2 to 3 times higher compared to RIA 
assessed albumin.  The authors conclude that because of a difference in albumin 
concentration measured by the two methods, new method-specific cut-off values 
should be applied. 48  
These previously performed studies all showed that the differences between the 
methods are especially evident in the lower albuminuria ranges (as assessed by 
immunochemical methods). Conclusions drawn by these studies are all based on the 
application of clinical cut-off values, however, all these studies used frozen urine 
samples to compare both methods. Freezing highly influences the HPLC assessed 
albumin concentration with a 55% decline after 1 year of storage at -20°C compared 
to a -30% change after 1 year when assessed by immunonephelometry (chapter 5). 
Storage at -80°C can furthermore not prevent a decline in HPLC assessed albumin. 
These results implicate that cut-off values should not be applied when using stored 
samples. Studies comparing the assessment of albumin by HPLC to immunochemical 
methods, and using classic cut-offs for micro- and macroalbuminuria should therefore 
be re-interpreted in terms of outcomes and conclusions. For this reason we used 
continuous levels of urinary albumin, instead of the traditionally used cut-off values, to 
study the predictive performance of albuminuria (assessed after storage for 7 years at -
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20°C) for total mortality assessed by immunonephelometry and HPLC (chapter 8). 
These analyses showed that both albuminuria assessed by immunonephelometry and 
HPLC are good predictors for mortality. We could furthermore demonstrate additional 
predictive properties of HPLC assessed albumin which can not be detected by ROC 
curves. Multivariate analysis showed that HPLC measured albuminuria results in a 
significantly higher hazard ratio in subjects with low immunonephelometry measured 
albuminuria compared to subjects with high immunonephelometry measured 
albuminuria. 
The poor relationship between the two methods in the low albumin concentration 
ranges, found in both studies, indicates that there is not a constant amount or 
proportion of immunochemically unreactive albumin that can be added to the amount 
of immunochemically reactive albumin, to derive the total amount excreted. An 
argument that is frequently brought forward in the discussion as to whether HPLC 
should be preferred above immunochemical methods is that it was shown in patients 
with type 1 and type 2 diabetes that HPLC measurement detects the onset of 
microalbuminuria respectively 3.9 and 2.4 years earlier compared to immunologic 
methods,49 making an earlier start of preventive interventions possible.  
Although several studies assume the superiority of HPLC over immunochemical 
detection, some limitations have been demonstrated. Sviridov et al. showed that major 
urinary components with the same molecular size as albumin, such as transferrin, α1-
acid glycoprotein, and α1-proteinase inhibitor, could not be separated from albumin in 
the HPLC assay.50 Due to peak tailing some larger proteins overlapped with albumin 
and could not be separated. A second limitation of the HPLC assay is that it is difficult 
to integrate the albumin peak properly. It is sometimes necessary to ‘guess’ where the 
true baseline for the albumin peak on the chromatogram lies.50 Sviridov et al. 
estimated that urinary globulins account for 20 to 30% of the albumin peak. On the 
other hand, Clavant and Comper et al. showed that other urinary proteins play no 
important role.49,51 These seemingly contradictory observations indicate that the 
reliability and sensitivity of the size-exclusion HPLC assay have yet to be established.  
 
What should we deduce from these data? It seems accurately demonstrated that urine 
indeed contains a varying amount of immunochemically unreactive albumin in 
addition to immunochemically reactive albumin. It could be that this 
immunochemically unreactive albumin, as well as possibly other proteins that are 
additionally detected by HPLC, are also predictive of future renal and cardiovascular 
events. Optimally, this should be investigated in a prospective study, using freshly 
collected urine samples. Such a study should show that the difference between the 
two assays is predictive of the future development of renal and cardiovascular events, 
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Table 1: Definition and classification of albuminuria 
 24 hour urine Timed overnight Spot (morning) sample 
 
 Albumin Albumin Albumin Albumin:creatinine ratio 
 (mg/24h) (μg/min) (mg/L)  (mg/mmol) (mg/g) 


















Abbreviations: M, male; F, female 
 
or that immunochemical albumin and HPLC are shown to be independent risk 
predictors. 
 
IS A LOWER CUT-OFF VALUE FOR THE DEFINITION OF MICROALBUMINURIA REQUIRED? 
The currently used definitions for microalbuminuria are presented in Table 1. 
Consensus about the definitions based on albumin excretion and albumin 
concentrations has been reached in the mid-nineties,52,53 whereas recommendations 
about the use of different cut-offs for ACR’s in men and women have been put 
forward later.33,34 In the mid-nineties, the most sensitive strips for detection of 
albuminuria had thresholds for detection of 20 mg/L.53 The lower limit of 30 mg/24 
hour for the definition of microalbuminuria has been chosen because this threshold of 
20 mg/L is multiplied by an average daily urinary output of 1.5 liters.  
 
The upper limit of 200 mg/L and 300 mg/24 hour has been determined by the fact 
that the sensitivity of the older strips for albumin was in the order of 100-300 mg/L.1,2 
The currently used cut-offs are therefore somewhat arbitrary, and not the result of 
prospective studies in which the best cut-off values have been defined. Recent studies 
have demonstrated that a continuous relationship exists between albumin excretion 
and cardiovascular risk. More importantly, subjects with subtle increases in urinary 
albumin excretion in the ‘normal’ range have been shown to be at increased risk for 
development of cardiovascular morbidity and mortality, and also for all cause 
mortality.9,10,12,15,53-57 In individuals with a high risk of CVD, as enrolled in the Losartan 
Intervention For Endpoint reduction (LIFE) and Heart Outcomes Prevention Evaluation 
(HOPE) trials risk for cardiovascular morbidity and mortality increased continuously as 
ACR increased.12,15 In the HOPE study, risk for cardiovascular events and all cause 
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mortality began to increase from an ACR of 1.9 mg/g, therefore well below the cut-off 
for microalbuminuria. The same is true for the risk for major cardiovascular events, 
which increased by 6% for every 3.5 mg/g increment in ACR. In the LIFE trial, risk 
began to increase from ACR levels of 2.2 mg/g. Every 10-fold increase in ACR 
corresponded to an increase of 55% in cardiovascular and total mortality, stroke and 
myocardial infarction.  
Recently, it was shown that levels of albuminuria below the threshold of 
microalbuminuria also predict the development of CVD in low risk patients. Middle 
aged, nondiabetic, nonhypertensive individuals were selected from the Framingham 
Heart Study. After adjustment for established cardiovascular risk factors, an ACR of  ≥ 
3.9 mg/g for men or ≥ 7.5 mg/g for women was associated with a 3-fold increased risk 
in CVD compared with subjects below the sex specific median.58  
Klaussen et al. suggested that the usual definition should be adjusted to lower levels 
than are presently used.56 A letter in response to this article pointed out that a minimal 
cut-off value can not be defined because there is a continuous increase in risk for 
cardiovascular death with increasing levels of urinary albumin excretion.59 As an 
explanation, one can think of the analogy with blood pressure. For diastolic and 
systolic blood pressure there is also a continuous increase in risk. Why then not lower 
the present JNC-7 advocated threshold of 140/90 mm Hg? This cut-off value has been 
defined because prospective placebo-controlled intervention studies have shown that 
antihypertensive treatment, in subjects with blood pressures above this cut-off, results 
in a valuable absolute risk reduction, at acceptable cost-effectiveness. In our opinion, 
redefining the minimal cut-off value for microalbuminuria should likewise be based 
upon clinical trials in which it is established that protective treatments, when started 
above that particular value, confer renal and cardiovascular protection versus no 
treatment, again at acceptable cost-effectiveness.58 
 
NOVEL BIOMARKERS  
Albuminuria as a biomarker has been thoroughly studied during the last decade with 
promising results. Good biomarkers are substances which are elevated in a diseased 
state and normal in healthy subjects. They should be easily measurable and detectable 
before the diseased state is reached, so effective treatment can be started early. One 
of the most extensively studied biomarkers is high-sensitive C-reactive protein (CRP) 
which plays an important role in the immune response by activating the classic 
complement pathway. It is generally believed that CRP represents the inflammatory 
component of atherosclerosis in the arterial vessel wall,60 and higher CRP levels have 
been identified in patients with myocardial infarction and stroke.61 In addition to CRP, 
other markers of inflammation have been studied such as sCD40L, which has been 
GENERAL DISCUSSION  
 105 
receiving growing attention. Soluble CD40 ligand is a platelet derived inflammatory 
marker of plaque rupture, and has been identified on endothelial cells, macrophages 
and monocytes.62, 63 Furthermore, sCD40L has been shown to be an independent 
predictor of cardiovascular disease.64 Other recently studied biomarkers are, amongst 
others, ICAM-1, VCAM-1, AGEs and NT-proBNP.  
The use of novel biomarkers in the screening for (vascular) inflammation might be an 
important tool to detect subjects at risk for cardiovascular disease. The simultaneous 
detection of these biomarkers might give us a broader view on the complex nature of 
cardiovascular disease. In this sense, the application of proteomics (large scale study 
of proteins) will have great opportunities by identifying new diagnostic biomarkers.  
Proteomics is a new method of analysis which can be performed in different sorts of 
biological samples such as urine, blood, cells and tissues. But also atherosclerotic 
plaques can be analyzed.65 The advantage of proteomics above genomics is that the 
body produces much more proteins (1,000,000) than there are genes that encode for 
those proteins (25,000). With proteomics, multiple proteins can be analyzed 
simultaneously, and this can give information on the effectiveness of treatment in 
patients, but is can also shed some light on the different stage of disease.                   
 
FUTURE PERSPECTIVES 
It is not known whether urinary albumin excretion is a risk factor or merely a risk 
marker. It is difficult to resolve this issue because most interventions that reduce 
albuminuria also affect blood pressure. Only trials that do not interfere in other 
cardiovascular and renal risk factors, such as blood pressure or serum cholesterol, can 
provide information whether reduction of albuminuria indeed confers protection in 
itself. In this respect it is interesting that recently the glycosaminoglycan sulodexide has 
become available for clinical research. This compound has been shown in pilot studies 
to lower albuminuria, without changing traditional cardiovascular risk factors. Several 
phase III studies have now been launched that aim at evaluating whether treatment of 
albuminuria with sulodexide can induce (independent of blood pressure increases) 
regression from microalbuminuria to normoalbuminuria in patients with type 2 
diabetes, and whether it increases time to first occurrence of End Stage Renal Disease 
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SUMMARY 
Albumin is the most abundant protein (65 kDalton) in human blood plasma. After 
being produced by the liver, albumin circulates as a polypeptide chain of 585 amino 
acids which is cross-linked by 17 disulphide bonds. Albumin contributes to about 80% 
of the colloid osmotic pressure, and it binds a variety of both self and non-self ligands 
such as hormones, fatty acids and drugs. Since the 1980s, it is known that the 
excretion of very small amounts of albumin in the urine (20-200 mg/L or 30-300 
mg/day), so called microalbuminuria, predicts the excretion of large amounts of 
proteins in the urine (proteinuria) in patients with diabetes mellitus. A few years later, 
microalbuminuria was also proven to be a powerful predictor of mortality in these 
patients. The clinical application of microalbuminuria as a laboratory risk marker is, to 
date, restricted to patients with diabetes mellitus. However, recent scientific research 
has shown that microalbuminuria is also an independent predictor of cardiovascular 
diseases and mortality in the general population. The underlying mechanism of these 
results is thought to be generalized endothelial dysfunction, expressed by the kidneys, 
resulting in ‘leakage’ of albumin into the urine. This endothelial dysfunction can be 
caused by risk factors such as high bloodpressure, smoking, obesity, and diabetes. 
Cardiovascular diseases are the leading cause of death in the Western world. The 
screening for subjects with an increased risk for cardiovascular diseases is therefore of 
utmost importance. In this respect, the detection of albumin in the urine plays a very 
important role.  
 
In this thesis we describe the effects of frozen storage of urine samples on the 
measured albumin concentration (part I). We furthermore explore the different 





Frozen storage of urine and blood samples before the assessment of the analyte of 
interest, is a common practice in large epidemiological and cohort studies. It is often 
easier (and cheaper) to analyse large amounts of specimens at the same time. In 
addition, the variation of an analytical assay is lower when measuring in a relatively 
short period of time because this makes it easier to monitor the circumstances in the 
laboratory.   
In chapter 2 we describe the effect of long-term storage (of up to 2 years) of urine 
samples at -20°C on the measured albumin concentration. The urine samples we used 
for this study contained albumin concentrations that were mainly in the normo- and 
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microalbuminuric range. First, we showed that sample preparation such as vortex-
mixing or applying hand-inversions is essential for a correct assessment of the albumin 
concentration in urine. Secondly, storage of up to 5 months has no significant effect 
on the albumin concentration. After 5 months, the average albumin concentration in 
the urine samples starts to decrease, and this decrease stabilizes to -30% until the end 
of the study after 12 months. This decrease was principally present in urine samples 
with a relatively low initial albumin concentration. An especially interesting finding of 
our study is the variability in percentage changes which indicates large differences 
between individual samples in their response to freezing. Although we were not able 
to further explore this phenomenon in this study, in chapter 3, we show that freezing 
indeed results in the introduction of a measurement error. Frozen storage furthermore 
results in a diminished predictive power of albuminuria for total mortality. 
 
Studying the cause of falsely low albumin concentrations after frozen storage was 
beyond the scope of chapters 2 and 3. To shed some light on possible mechanisms of 
decrease, we investigated the potential relationship between the initial pH of urine 
and a decline after storage. Chapter 4 demonstrates that the urinary pH is associated 
with the magnitude of decline in urinary albumin assessed after frozen storage for one 
year. There is a clear relation between lower pH of the urine and a change in albumin 
concentration after storage. This can be explained by the isoelectric point of albumin 
being 4.7, resulting in aggregation and denaturation of albumin molecules at low pH.      
An often proposed possibility to prevent falsely low albumin concentrations, is to store 
urine samples at -80°C instead of -20°C. Surprisingly, this has never been properly 
investigated. In chapter 5, the effects of storage at different temperatures are 
compared, and indeed, storing samples at -80°C could prevent the decline in albumin 
concentrations after 12 months while storage at -20°C again resulted in a -30% 
change. Secondly, we studied whether using a different assay (high performance liquid 
chromatography (HPLC)) to measure albumin can prevent a change in albumin after 
storage. We found that the consequences of freezing on HPLC assessed albumin are 
much larger than on immunonephelometry. A decline in HPLC assessed albumin 
concentration could not be prevented by storing the samples at -80°C. Surprisingly, 
the relation between urinary pH and a decline in measured albumin concentration 
when assessed by immunonephelometry was not found when measuring by HPLC. 
 
              
PART II 
Albuminuria can be measured in several ways: 1) in a spot morning urine sample 
(mg/L), 2) as albumin:creatinine ratio (ACR, mg/g) and 3) in a 24 hour urine collection 
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as albumin excretion per 24 hour which is generally considered as the ‘gold standard’. 
However, the latter procedure is cumbersome and can be inaccurate due to collection 
errors. On the other hand, the albumin to creatinine ratio is accompanied with extra 
costs. There is an ongoing debate whether either albumin concentration or the 
albumin to creatinine ratio from a spot morning void can be used as alternatives, and 
which one of these is the best. In Chapter 6 we describe several aspects which we 
think should be taken into consideration when making the choice between the 
different ways to measure albumin in urine. These considerations apply to both the 
clinical setting and epidemiological trials. As we have shown in the first part of this 
thesis, it is important to know whether the albumin concentration is assessed in fresh 
or frozen samples. In addition, 24 hour urine samples should not be used as a 
substitute for a single urine sample which is common practice in large clinical studies.  
 
Traditionally, albumin in the urine is measured by immunochemical methods such as 
immunonephelometry and radio-immuno-assay. These methods are based on the 
formation of antigen-antibody complexes which precipitate and can be measured with 
so called ‘scatterlight’. Recent research has shown that urine not only contains 
immunochemically reactive albumin, but also another protein/albumin fraction. This 
intact form of albumin is believed to be the product of diminished lysosomal activity in 
the kidney, consequently resulting in the disruption of the immunochemically reactive 
activity of the albumin molecule. This ‘immunochemically unreactive albumin’ is similar 
to immunochemically reactive albumin with respect to size, form, and charge, and can 
be measured by a newly developed HPLC method based on size-exclusion. In 
Chapter 7 we compared the analytical properties and clinical value of albuminuria 
assessed by immunonephelometry and HPLC. HPLC measures higher albumin 
concentrations, especially present in the lower albuminuria ranges 
(immunonephelometry as reference: <200 mg/L). Consequently, the prevalence of 
subjects with microalbuminuria is much lower when albumin is assessed by HPLC than 
by immunonephelometry. When applying the classic cut-off values we found HPLC 
assessed albumin to show a stronger relation with peripheral vascular disease than 
albuminuria assessed by immunonephelometry. However, we could not find this 
relation by applying continuous levels of albuminuria (ROC analysis). The question 
then is, whether classic cut-off values should be applied when measuring with HPLC, 
or whether method-specific cut-off values should be defined. Furthermore, as 
described in chapter 5, freezing has large consequences on immunonephelometry but 
especially on HPLC assessed albumin. Because of these two reasons, clinical cut-off 
values should not be used when comparing these methods. That is why, in chapter 8, 
the predictive performance of albuminuria (after storage for 7 years at -20°C) assessed 
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by immunonephelometry and HPLC was studied on a continuous scale. Both HPLC 
and immunonephelometry measured albumin is a good predictor of (cardiovascular) 
mortality. In addition, albuminuria assessed by HPLC and immunonephelometry are 
additive in the prediction for both cardiovascular and total mortality. HPLC measured 
albuminuria results in a higher hazard ratio for mortality in subjects with low 
immunonephelometry measured albuminuria compared to subjects with high 
immunonephelometry measured albuminuria.  
 
Chapter 9 gives a general overview on the research described in this thesis.  
 
In conclusion, the frozen storage of urine samples at -20°C in large epidemiological 
studies has a large implication on the design and interpretation of these studies and 
should therefore be avoided. Although storage at -80°C might be an acceptable 
alternative, further studies on the potential increase in variability have to be performed 
to demonstrate that urine samples stored at this temperature can indeed safely be 
used to assess the albumin concentration.  
Urine contains varying amounts of immunochemically reactive and immunochemically 
unreactive albumin. This total albumin can be determined by HPLC and is, similar to 
immunonephelometry assessed albuminuria, a good predictor of mortality. Moreover, 
albuminuria assessed by HPLC and immunonephelometry are additive in the 
prediction for mortality. Prospective studies, using fresh urine samples should be 
performed to show that HPLC measured albumin is also a good predictor of renal end-
points.             





















Albumine is het meest voorkomende eiwitmolecuul (65 kDalton) in humaan bloed 
plasma. De belangrijkste functie van albumine is het behoud van de colloid-
osmotische druk. Daarnaast speelt het een rol in het transport van diverse 
lichaamseigen (hormonen en vetzuren) en lichaamsvreemde stoffen (geneesmiddelen).  
Sinds de jaren ’80 is reeds bekend dat de excretie van kleine hoeveelheden albumine 
in de urine, micro-albuminurie genoemd, het uitscheiden van grote hoeveelheden 
eiwit in de urine (proteïnurie) voorspelt in patiënten met suikerziekte (diabetes 
mellitus). Enkele jaren later werd ontdekt dat micro-albuminurie ook een goede 
voorspeller is van sterfte (mortaliteit) in deze patiëntengroep. Tot op heden is de 
klinische toepassing van micro-albuminurie als laboratorium risico marker beperkt 
gebleven tot de patiëntengroep met diabetes mellitus. Echter, de laatste jaren heeft 
wetenschappelijk onderzoek aangetoond dat micro-albuminurie ook een 
onafhankelijke voorspeller is van hart- en vaatziekten en mortaliteit in de algemene 
populatie. De achterliggende gedachte is dat albuminurie het gevolg is van 
gegeneraliseerde vaatschade dat tot uiting komt in de nieren, waardoor albumine in 
de urine ‘lekt’. Deze vaatschade kan ontstaan door bepaalde risicofactoren zoals hoge 
bloeddruk, overgewicht, diabetes en roken.  
 
Hart- en vaatziekten zijn de belangrijkste oorzaak van sterfte in de westerse 
samenleving. Het is dan ook van groot belang dat mensen met een verhoogd risico op 
hart- en vaatziekten opgespoord en behandeld worden. Detectie van albumine in de 
urine kan daarin een belangrijke rol spelen.  
 
Dit proefschrift beschrijft enerzijds de effecten die het bevroren opslaan van urine 
monsters kan hebben op de albumine concentratie (deel I). Anderzijds gaat het dieper 
in op de verschillende meettechnieken die een rol spelen in de analyse van albumine 




Het komt regelmatig voor dat in grote epidemiologische- en cohort studies urine en 
bloed monsters bevroren opgeslagen worden. De reden daarvan is, dat het vaak 
eenvoudiger (en goedkoper) is om grote aantallen monsters in één keer te analyseren. 
Wanneer in een relatief korte tijdspanne gemeten wordt, blijft daarnaast de variatie 
van een analytische bepaling lager doordat de laboratoriumomstandigheden beter 
constant gehouden kunnen worden.  
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Hoofdstuk 2 van dit proefschrift beschrijft het effect van langdurige opslag (tot 2 jaar) 
van urinemonsters bij -20°C op de albumine concentratie. De monsters die wij hebben 
gebruikt voor dit onderzoek hadden een albumine concentratie die voornamelijk in 
het normo- en micro-albuminure gebied lag. In dit hoofdstuk laten wij allereerst zien 
dat het voorbewerken van monsters door te vortexen of te zwenken essentieel is voor 
een correcte albumine bepaling. Het toont verder aan, dat, hoewel er geen verschillen 
in albumine concentratie te zien waren tot 5 maanden van bevroren opslag, na 5 
maanden de gemiddelde albumine concentratie ten opzichte van de verse 
concentratie af begon te nemen tot uiteindelijk een stabilisatie van de afname van 
ongeveer 30% plaatsvond. Deze afname is met name te zien in monsters met een 
relatief lage albumine concentratie. Een interessante bevinding in deze studie is dat 
vriezen vermoedelijk gepaard gaat met een toename in variabiliteit. Met andere 
woorden, verschillende urine monsters reageren verschillend op het vriezen, wat 
bijvoorbeeld resulteert in een afname van 60% in één urinemonster terwijl een 
toename van 10% te zien is in een volgend monster. Deze bevinding werd concreet 
bevestigd in hoofdstuk 3: vriezen gaat gepaard met de introductie van een meetfout. 
Daarnaast laten wij in dit hoofdstuk zien dat het bevroren opslaan van monsters 
gepaard gaat met een verminderd voorspellend vermogen van albuminurie voor totale 
mortaliteit.  
 
Hoofdstukken 2 en 3 van het proefschrift gaan niet dieper in op de oorzaak (of 
oorzaken) van foutief lage albumine concentraties na opslag. In de literatuur wordt 
een relatie tussen de pH van de urine en een verschil na vriezen vaak gesuggereerd. 
Een mogelijke verklaring hiervoor is het lage iso-electrisch punt van albumine 
waardoor bij een lage pH de albumine moleculen gaan aggregeren en denatureren. 
Uit hoofdstuk 4 blijkt dat de pH van de urine inderdaad een rol speelt in het ontstaan 
van een verschil in albumine concentraties na opslag: een lagere pH van de urine gaat 
gepaard met een groter verschil in albumine concentratie.  
 
Er wordt regelmatig gesuggereerd dat opslag van urine monsters bij -80°C foutief lage 
albumine waarden kan voorkomen. Dit is echter nooit goed onderzocht. In hoofdstuk 
5 worden de effecten van opslag van urine monsters bij -20°C vergeleken met opslag 
bij -80°C. Het bij -80°C opslaan van monsters blijkt inderdaad een verschil in albumine 
concentratie te kunnen voorkomen, terwijl opslag bij -20°C wederom een verschil van 
-30% laat zien ten opzichte van vers gemeten monsters zoals ook al naar voren kwam 
in hoofdstukken 2 en 3. Verder wordt in deze studie gekeken of er na vriezen een 
verschil in albumine concentratie is wanneer een andere meetmethode gebruikt 
wordt. Voor dit onderzoek werd de albumine concentratie bepaald met zowel de 
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traditionele methode (immunonefelometrie) als met een nieuw ontwikkelde high-
performance liquid chromatography (HPLC) methode. Een opvallende bevinding is dat 
HPLC gemeten albumine grotere gevolgen ondervindt van vriezen dan 
immunonefelometrie gemeten albumine. Daarnaast kan het verschil in HPLC gemeten 
albumine niet volledig voorkomen worden door opslag bij -80°C, in tegenstelling tot 
het met immunonefelometrie gemeten albumine. Ook de relatie tussen de pH van de 
urine en het verschil in albumine na vriezen kon voor HPLC bepaald albumine niet 




Albuminurie kan op verschillende manier gemeten worden: 1) in een ochtend urine 
monster als albumine concentratie (mg/L), 2) als de albumine:creatinine ratio (mg/g), 
of 3) in een 24 uur urine verzameling als albumine excretie in mg per 24 uur, welke 
wordt beschouwd als de ‘gouden standaard’. Het verzamelen van een 24 uur monster 
is echter belastend en onnauwkeurig vanwege fouten tijdens het verzamelen. 
Daarentegen gaat het meten van de albumine:creatinine ratio gepaard met extra 
kosten. In hoofdstuk 6 worden verschillende facetten beschreven waarmee rekening 
gehouden dient te worden bij de keuze welk soort urine monster te gebruiken voor 
de bepaling van albumine. Dit geldt voor het klinische kader maar ook in 
epidemiologische studies. Belangrijke aspecten die wij benoemen bij de interpretatie 
van de resultaten is de vraag of de albumine concentratie in verse of bevroren urine 
monsters gemeten. Hiervan zijn de gevolgen beschreven in het eerste deel van dit 
proefschrift. Daarnaast is een belangrijke conclusie dat een portie van een 24 uur 
verzameling niet gebruikt kan worden als surrogaat voor een enkel urine portie wat 
regelmatig voorkomt in grote studies.  
 
Van oudsher wordt het albumine in de urine gemeten met immuno-chemische 
technieken zoals immunonefelometrie en radio-immuno-assay. Deze methoden zijn 
gebaseerd op het principe van de vorming van een product tussen een antilichaam 
met een antistof wat vervolgens een precipitaat vormt en waarvan de intensiteit 
gemeten wordt met behulp van zogenaamd ‘strooilicht’. Recent onderzoek heeft 
echter aangetoond dat urine niet alleen immuno-chemisch albumine, maar ook nog 
een andere fractie bevat. Van deze intacte vorm van albumine wordt gedacht dat het 
een product is van een verminderde lysosomale activiteit in de nier wat resulteert in 
een verstoring van de immuno-reactieve bindingsplek die zich aan het molecuul 
bevindt. Dit ‘niet-immunoreactieve albumine’ is qua vorm, grootte en lading hetzelfde 
als het immuno-reactieve albumine en kan gemeten worden met behulp van HPLC 
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gebaseerd op het principe van selectie op deeltjesgrootte. Deze nieuw ontwikkelde 
methode meet beide soorten albumine, ook wel totaal intact albumine genoemd. In 
hoofdstuk 7 wordt met immunonefelometer gemeten albumine vergeleken met HPLC 
gemeten albumine. HPLC laat hogere albumine waarden zien in vergelijking met 
immunonefelometrie en dit verschil is met name aanwezig in de lage concentratie 
gebieden (immunonefelometrie als referentie, <200 mg/L). Dit verschil in concentratie 
heeft tot resultaat dat de prevalentie van micro-albuminuren hoger is met HPLC dan 
met immunonefelometrie gemeten albumine wanneer de traditionele klinische 
afkapwaarden gebruikt worden. ROC analyse liet zien dat er geen verschil was in 
relatie tussen het immunonefelometrie en HPLC gemeten albumine en perifere 
vaatziekte. Echter, wanneer de klinische afkapwaarden toegepast worden, blijkt het 
HPLC gemeten albumine wel een sterkere relatie te vertonen met perifere vaatziekte. 
Een belangrijke kanttekening die bij deze bevinding geplaatst moet worden is, of het 
met het oog op het verschil in albumine concentratie, in deze situatie wel terecht is 
dat deze afkapwaarden toegepast worden. Daarnaast laat hoofdstuk 5 zien dat 
albumine in urine sterk onder invloed staat van het effect van vriezen. Om die twee 
redenen kunnen klinische afkapwaarden niet gebruikt worden. Daarom wordt in 
hoofdstuk 8 het verschil in predictieve waarde voor totale en cardiovasculaire 
mortaliteit tussen de door beide methoden gemeten albuminurie (na opslag 
gedurende 7 jaar bij -20°C) op continue schaal bestudeerd. Beide methoden blijken 
goede voorspellers van totale mortaliteit. HPLC gemeten albumine heeft een 
toegevoegde voorspellende waarde boven immunonefelometrie gemeten albumine. 
Personen met hoge HPLC gemeten albumine waarden in hun urine, in combinatie met 
lage immunonefelometer gemeten albumine waarden in hetzelfde urinemonster, 
hebben een hoger (cardiovasculair) mortaliteits risico dan personen met een hoge 
albumine waarde gemeten door beide methoden. 
 
De algemene discussie over het in dit proefschrift beschreven onderzoek is te vinden 
in hoofdstuk 9.  
 
Concluderend, het bij -20°C bevroren opslaan van urine monsters voor de bepaling 
van albumine in grote epidemiologische studies, heeft aanzienlijke gevolgen voor het 
design en de interpretatie van deze studies en kan om die reden dan ook niet 
zondermeer gebruikt worden. Hoewel het bewaren van urine monsters bij -80°C een 
goed alternatief lijkt, zullen vervolg studies nodig zijn om aan te tonen dat deze 
monsters daadwerkelijk gebruikt kunnen worden en dat dit geen toename van 
variabiliteit tot gevolg heeft zoals wel het geval is bij opslag bij -20°C. 
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Urine bevat wisselende hoeveelheden immuno-reactief en niet-immuno-reactief 
albumine. Dit totaal albumine kan bepaald worden door HPLC en voorspelt mortaliteit 
in dezelfde mate als het immuno-reactieve albumine maar heeft daarnaast ook nog 
een toegevoegde voorspellende waarde. Prospectieve studies, met verse urine 
monsters, zullen gedaan moeten worden om aan te tonen dat HPLC gemeten 
albumine ook een voorspeller is van renale eindpunten.                             
 








De letterlijke definitie van promoveren volgens de Grote Van Dale is als volgt: 
 
pro·mo·ve·ren (onov.ww.) 
1 de graad van doctor verwerven => doctoreren 
2 naar een hogere klasse, functie overgaan 
 
Hoewel deze definitie in essentie klopt, is promoveren veel meer dan dat. Promoveren 
vereist hard werken, discipline, doorzettingsvermogen en ambitie. Daarnaast is het 
een leerproces waarbij je geniet van de ‘ups’ en leert omgaan met de ‘downs’. Het 
mooiste van promoveren is dat je de uitdaging aangaat met tientallen mensen die op 
allerlei verschillende manieren met je mee-promoveren. Daarom wil ik iedereen die 
heeft bijgedragen aan de totstandkoming van dit proefschrift hartelijk bedanken. Een 
aantal wil ik persoonlijk noemen. 
 
Bijna vier jaar geleden sloot ik mijn afstudeerproject voor Farmacie af en wilde 
aansluitend promotieonderzoek gaan doen. Dankzij Lolkje de Jong-van den Berg 
kwam ik in contact met Paul de Jong en het PREVEND onderzoek. Ik kreeg de kans 
mijn promotieonderzoek te gaan uitvoeren binnen deze unieke studie, mogelijk 
gemaakt door duizenden Groningers. 
 
Mijn eerste woord van dank gaat uit naar de vijf mannen zonder wie dit proefschrift er 
niet geweest zou zijn.  
Mijn eerste promotor Prof. Dr. Dick de Zeeuw. Beste Dick, jouw creativiteit, 
gedrevenheid en enthousiasme zijn van onschatbare waarde geweest voor mijn 
proefschrift. Ik wil je hartelijk danken voor het vertrouwen dat jij in mij gehad hebt 
toen we samen aan dit project begonnen.  
Mijn tweede promotor Prof. Dr. Paul E. de Jong. Beste Paul, ik ben je zeer dankbaar 
voor de vriendelijke woorden en opbouwende kritiek die je mij telkens weer gaf na 
het altijd supersnelle lezen van mijn stukken. Het was fijn om te weten dat ik altijd bij 
je terecht kon. 
Mijn co-promotor en directe begeleider Dr. Stephan J.L. Bakker. Beste Stephan, ik heb 
enorm veel geleerd van jouw ‘geneuzel’ zoals jij dat altijd noemde. Ik bewonder de 
energie waarmee jij kunt blijven graven en zoeken in de data, met prachtige artikelen 
tot resultaat. Jouw brede kennis en tomeloze inzet hebben een essentiële bijdrage 
geleverd aan dit proefschrift en daar ben ik je dan ook zeer dankbaar voor. 
Mijn co-promotor Dr. Ron T. Gansevoort. Beste Ron, na ruim drie jaar met jou 
gewerkt te hebben weet ik wat men bedoeld met ‘een heldere blik op het onderzoek 
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hebben’. Jij gaf telkens weer een verfrissende kijk op de data en mijn artikelen. 
Daarnaast heb jij mij geleerd een link met de kliniek te trekken in alles wat ik deed.  
Last, but certainly not least: mijn co-promotor Dr. Ido P. Kema. Beste Ido, jij hebt aan 
de basis gestaan van mijn loopbaan en bent betrokken geweest bij de keuzes die ik 
maakte van HLO-student naar analist, van Farmacie student naar promovendus en 
postdoc. Ik ben je dankbaar voor de vele adviezen die je mij gegeven hebt, ze zijn 
voor mij van onschatbare waarde geweest. Ik ben dan ook erg blij dat jij mijn co-
promotor wilde zijn en ik ben je dankbaar dat je telkens weer tijd wist te vinden in je 
drukke schema voor een afspraak of het lezen van mijn stukken. 
 
Ik wil de leden van de beoordelingscommissie, Prof. Dr. P.C. Limburg, Prof. Dr. R.P. 
Stolk en Prof. Dr. R.J. Vonk hartelijk bedanken voor de bereidheid mijn proefschrift te 
beoordelen. 
 
De PREVEND databank zou er niet zijn zonder de inzet van de medewerkers van het 
Trial Coordination Center. Een woord van dank gaat dan ook uit naar Dr. Hans L. 
Hillege, Onno van der Velde, Rob Bieringa en Marco Assman. 
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gevoeld. Speciale dank gaat uit naar Jacko, Janneke en Bettine: voor de gezelligheid 
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vragen. De Nefrologie was mijn tweede thuis en niet in de laatste plaats door Winie’s 
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nuchterheid en kalmte. Die eigenschappen zullen je tot een geweldige cardioloog 
maken. Ik vond het erg jammer dat je vertrok, maar je had een hele goede reden!  
Auke, we begonnen samen en hebben samen het hele proces doorlopen. Jouw 
eigenwijsheid en standvastigheid hebben de boel menigmaal ‘opgeleukt’. Ik bewonder 
de manier waarop jij telkens weer je doel weet te bereiken. Het zal je ver brengen! 
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elkaar op de kamer te gaan zitten. Dat zou veel te gezellig worden. En gezellig was 
het! Het is bijzonder als je, zonder een woord te wisselen, weet wat de ander denkt. 
Marije, het was leuk om jou als nieuwe onderzoeker te mogen verwelkomen en je een 
beetje wegwijs te kunnen maken in de ‘wondere wereld’ van het Kidney Center. Ik 
wens je veel succes en plezier op de PREVEND de komende jaren.  
Akin en Riko, ik heb genoten van jullie boeiende verhalen en ervaringen uit de kliniek! 
  
De assistentes en studenten van de PREVEND polikliniek hebben gezorgd voor een 
warm ontvangst elke ochtend weer. Anna, Annet, Annie, Martha en Roelie, ik kon 
altijd bij jullie terecht voor een praatje en het uiten van mijn frustraties. Bedankt voor 
de vele kopjes (kaneel) thee (met twee (of drie) klontjes suiker) en vele 
boterhammetjes (en soms een kroketje) samen!  
 
Mirjan, jouw heerlijke nuchterheid en de manier waarop je met weinig, maar soms 
ook met heel veel woorden, gezelligheid bracht tijdens de etentjes, lunches, 
congressen en PLAN-dagen (zelfs als we stranden in Breda omdat de NS ons in de 
steek laat) zijn erg belangrijk voor me geweest. Ik ben dan ook erg blij dat jij naast me 
staat als paranimf en ben er trots op dat ik voor jou hetzelfde mag doen.  
 
Michel, een echte vriend staat altijd voor je klaar (als paranimf zelfs in de letterlijke 
zin). Jij bent een echte vriend! Binnenkort met Andrea naar Ierland? 
DANKWOORD 
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